

101.422-24/03 – including *Taq* polymerase  
 101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

**Olerup SSP<sup>®</sup> HLA-A\*24**

<b>Product number:</b>	101.422-24/03 – including <i>Taq</i> pol. 101.422-24u/03u – without <i>Taq</i> pol.
<b>Lot number:</b>	3R9
<b>Expiry date:</b>	2026-11-01
<b>Number of tests:</b>	24 tests – Product No. 101.422-24/24u 3 tests – Product No. 101.422-03/03u
<b>Number of wells per test:</b>	95+1
<b>Storage - pre-aliquoted primers:</b>	dark, between -15°C and -25°C
- PCR Master Mix:	between -15°C and -25°C
- Adhesive PCR seals	RT

**This Product Description is only valid for Lot No. 3R9.**

Complete product documentation consists of generic Instructions for Use (IFU), lot specific Product Insert, Worksheet and Certificate.

**CHANGES COMPARED TO THE PREVIOUS OLERUP SSP<sup>®</sup>  
 HLA-A\*24 LOT (2L4)**

- The product documentation has been updated for new alleles of IMGT 3.49.0.
- The kit resolution focuses on common and well documented (CWD) alleles<sup>1</sup>.

- <sup>1</sup>As described in section Uniquely Identified Alleles.

The HLA-A\*24 specificity and interpretation tables have been updated for the HLA-A alleles described since the previous *Olerup SSP<sup>®</sup>* HLA-A\*24 lot was made (**Lot No. 2L4**).

The primers of the wells detailed below have been exchanged, added or modified compared to the previous lot.

Well	5'-primer	3'-primer	rationale
3	Modified	-	5'-primer modified for improved allelic resolution.
5	Modified	-	5'-primer modified for improved allelic resolution.
21	-	Exchanged	3'-primer exchanged for improved HLA-specific amplification.
24	-	Modified	3'-primer modified for improved specificity of HLA-specific primer pair.

<sup>1</sup>S. J. Mack, P. Cano, J. A. Hollenbach et al.  
 Common and well-documented HLA alleles: 2012 update to the CWD catalogue. *Tissue Antigens*, 2013, 81, 194–203



**0197**

101.422-24/03 – including *Taq* polymerase  
101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

Well **96** contains Negative Control primer pairs, that will amplify the majority of the *Olerup* SSP<sup>®</sup> HLA Class I, DRB, DQB1, DPB1 and DQA1 amplicons as well as all the amplicons generated by the control primer pairs matching the human growth hormone gene.

HLA-specific PCR product sizes range from 75 to 200 base pairs.

The PCR product generated by the positive control primer pair is 200 base pairs.

Length of PCR product	105	200	105	80	75	80	85
<b>5'-primer<sup>1</sup></b>	<b>164</b>	<b>340</b>	<b>440</b>	<b>45</b>	<b>45</b>	<b>43</b>	<b>36</b>
	5'-CAC <sup>3'</sup>	5'-Agg <sup>3'</sup>	5'-TTA <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-TAC <sup>3'</sup>
							36
							5'-TAT <sup>3'</sup>
<b>3'-primer<sup>2</sup></b>	<b>231</b>	<b>2<sup>nd</sup> I</b>	<b>507</b>	<b>59</b>	<b>58</b>	<b>57</b>	<b>47</b>
	5'-TgC <sup>3'</sup>	5'-AAA <sup>3'</sup>	5'-TTg <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-ggC <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-ACA <sup>3'</sup>
							48
							5'-gCA <sup>3'</sup>
							48
							5'-gCC <sup>3'</sup>
							52
							5'-TgT <sup>3'</sup>
<b>A*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>B*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>C*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>DRB1</b>				<b>+</b>	<b>+</b>		
<b>DRB3</b>				<b>+</b>	<b>+</b>		
<b>DRB5</b>				<b>+</b>			
<b>DQB1</b>					<b>+</b>		
<b>DPB1</b>						<b>+</b>	
<b>DQA1</b>							<b>+</b>

<sup>1</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide and codon numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>2</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon or the 2<sup>nd</sup> intron, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide and codon numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: November 2022, Rev. No: 00

101.422-24/03 – including *Taq* polymerase  
101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

## PRODUCT DESCRIPTION

### HLA-A\*24 SSP subtyping

#### CONTENT

The primer set contains 5'- and 3'-primers for identifying the HLA-A\*24:02 to A\*24:578 alleles.

#### PLATE LAYOUT

Each test consists of 96 PCR reactions in a 96 well PCR plate.

1	2	3	4	5	6	7	8
9	10	11	12	13	14	15	16
17	18	19	20	21	22	23	24
25	26	27	28	29	30	31	32
33	34	35	36	37	38	39	40
41	42	43	44	45	46	47	48
49	50	51	52	53	54	55	56
57	58	59	60	61	62	63	64
65	66	67	68	69	70	71	72
73	74	75	76	77	78	79	80
81	82	83	84	85	86	87	88
89	90	91	92	93	94	95	NC

The 96 well PCR plate is marked with ‘HLA-A\*24’ in silver/gray ink.

Well No. 1 is marked with ‘3R9’.

Wells 1 to 95 – HLA-A\*24 high resolution primers.

Well 96 – Negative Control.

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays, and should be disregarded. The PCR plates are covered with a PCR-compatible aluminium foil.

#### INTERPRETATION

Due to the sharing of sequence motifs between HLA-A alleles some non-HLA-A\*24 alleles will be amplified by some primer mixes. For further details see Specificity Table.

#### UNIQUELY IDENTIFIED ALLELES

All the HLA-A\*24 alleles, i.e. **A\*24:02 to A\*24:578**, recognized by the HLA Nomenclature Committee in July 2022<sup>1,2</sup>, will be amplified by the primers in the HLA-A\*24 subtyping kit<sup>3</sup>.

The HLA-A\*24 kit enables separation of the confirmed HLA-A\*24 alleles as listed in the IMGT/HLA database 3.27.0. An HLA allele is listed as confirmed by IMGT/HLA



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: November 2022, Rev. No: 00

101.422-24/03 – including *Taq* polymerase  
101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **3R9**

**Lot-specific information**

if it has been sequenced by more than a single laboratory or from multiple sources. Current allele confirmation status for HLA-A\*24 alleles is listed below.

The HLA-A\*24 kit also enables identification of many null and alternatively expressed alleles.

The following HLA-A\*24 alleles can be distinguished by the different sizes of the HLA-specific PCR product:

Alleles	Primer mix	Alleles	Primer mix
A*24:29, 24:271	29	A*24:84N, 24:218	73
A*24:37, 24:119	31	A*24:101, 24:111	83
A*24:47, 24:232N	36	A*24:102, 24:103	84
A*24:49:01-24:49:02, 24:126	38	A*24:104, 24:117	85
A*24:60N, 24:205	55	A*24:105, 24:121	86
A*24:72, 24:297	62	A*24:106, 24:136, 24:330	87
A*24:76, 24:98	76	A*24:115, 24:234	90
A*24:78, 24:353	68	A*24:116, 24:352	88
A*24:79, 24:249	67	A*24:135:01-24:135:02, 24:238	91
A*24:80, 24:184	69	A*24:206, 24:322	90, 94
A*24:81, 24:134	70	A*24:225:01-24:225:02, 24:240N	69, 83
A*24:82, 24:128	71	A*24:231, 24:410	95

<sup>1</sup>HLA-A alleles listed on the IMGT/HLA web page 2022-July-12, release 3.49.0, [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla).

<sup>2</sup>Alleles that have been deleted from or renamed in the official WHO HLA Nomenclature up to and including the last IMGT/HLA database release can be retrieved from web page <http://hla.alleles.org/alleles/deleted.html>.

<sup>3</sup>The HLA-A\*24 primer set cannot separate the following alleles. These alleles can be distinguished by the HLA-A low resolution and/or HLA-A\*02, HLA-A\*23 and HLA-A\*33 kits.

**Alleles**

A\*24:02:01:01, 24:02:01:03-24:02:02, 24:02:04, 24:02:06-24:02:09, 24:02:11-24:02:64, 24:02:66-24:02:88, 24:02:90-24:02:99, 24:02:101-24:02:122, 24:02:124-24:02:155, 24:147-24:154, 24:161-24:162, 24:165-24:166, 24:170-24:172:02, 24:174-24:176, 24:178-24:179, 24:181, 24:186-24:187, 24:189, 24:193, 24:195, 24:198, 24:200-24:203, 24:209, 24:212, 24:214, 24:216-24:217, 24:221, 24:223-24:224, 24:226:01-24:226:02, 24:230, 24:236-24:237, 24:239, 24:241-24:247, 24:254, 24:257-24:259, 24:261-24:262, 24:272-24:274, 24:277, 24:279, 24:281-24:282, 24:284, 24:286, 24:292, 24:295, 24:298, 24:301, 24:305-24:306, 24:311, 24:313:01-24:313:02, 24:317-24:318, 24:320-24:321, 24:325-24:326, 24:328, 24:332, 24:334-24:336, 24:338, 24:341, 24:343, 24:346, 24:350-24:351, 24:358, 24:360-24:366, 24:368-24:369, 24:371-24:372, 24:375-24:376, 24:378Q, 24:380, 24:382-24:386, 24:388N-24:389N, 24:391, 24:393-24:394, 24:396N-24:398, 24:400-24:403, 24:407, 24:411, 24:413, 24:415-24:423, 24:425N-24:440, 24:442-24:445N, 24:447Q-24:449, 24:451-24:452, 24:454-24:456N, 24:460:01:01-24:460:01:02, 24:463-24:470, 24:473Q-24:476, 24:479Q-24:480, 24:482, 24:484-24:487, 24:490-24:493, 24:496-24:497, 24:500-24:502, 24:505, 24:507-24:509, 24:511-24:513Q, 24:516-24:523, 24:525-24:526, 24:529N-24:531, 24:533-24:534, 24:536Q-24:539, 24:543, 24:545-24:550, 24:552-24:554, 24:556N, 24:558, 24:560-24:561, 24:564-24:565, 24:567N-24:568N, 24:571, 24:573, 24:575-24:578, 23:113N  
A\*24:13:01-24:13:02, 23:104  
A\*24:164, 24:373, 24:399, 24:405, 24:446, 24:572, 02:804, 33:19  
A\*24:555, 33:21



0197

101.422-24/03 – including *Taq* polymerase  
101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

**ALLELE CONFIRMATION STATUS**

Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>
A*24:02:01:01	Confirmed	A*24:02:42	Unconfirmed	A*24:02:92	Unconfirmed	A*24:35	Unconfirmed
A*24:02:01:02L	Confirmed	A*24:02:43	Unconfirmed	A*24:02:93	Unconfirmed	A*24:36N	Confirmed
A*24:02:01:03	Unconfirmed	A*24:02:44	Unconfirmed	A*24:02:94	Unconfirmed	A*24:37	Confirmed
A*24:02:01:04	Confirmed	A*24:02:45	Unconfirmed	A*24:02:95	Unconfirmed	A*24:38	Unconfirmed
A*24:02:01:05	Confirmed	A*24:02:46	Unconfirmed	A*24:02:96	Unconfirmed	A*24:39	Confirmed
A*24:02:01:06	Unconfirmed	A*24:02:47	Unconfirmed	A*24:02:97	Confirmed	A*24:40N	Unconfirmed
A*24:02:01:07	Unconfirmed	A*24:02:48	Unconfirmed	A*24:02:98	Confirmed	A*24:41	Unconfirmed
A*24:02:01:08	Unconfirmed	A*24:02:49	Confirmed	A*24:02:99	Unconfirmed	A*24:42	Unconfirmed
A*24:02:01:09	Unconfirmed	A*24:02:50	Unconfirmed	A*24:02:100	Unconfirmed	A*24:43	Confirmed
A*24:02:01:10	Unconfirmed	A*24:02:51	Unconfirmed	A*24:03:01:01	Confirmed	A*24:44	Unconfirmed
A*24:02:02	Confirmed	A*24:02:52	Unconfirmed	A*24:03:01:02	Confirmed	A*24:45N	Unconfirmed
A*24:02:03Q	Unconfirmed	A*24:02:53	Confirmed	A*24:03:02	Confirmed	A*24:46	Confirmed
A*24:02:04	Confirmed	A*24:02:54	Unconfirmed	A*24:03:03	Confirmed	A*24:47	Confirmed
A*24:02:05	Confirmed	A*24:02:55	Unconfirmed	A*24:03:04	Unconfirmed	A*24:48N	Unconfirmed
A*24:02:06	Confirmed	A*24:02:56	Unconfirmed	A*24:04	Confirmed	A*24:49	Unconfirmed
A*24:02:07	Unconfirmed	A*24:02:57	Unconfirmed	A*24:05:01	Confirmed	A*24:50	Confirmed
A*24:02:08	Unconfirmed	A*24:02:58	Confirmed	A*24:05:02	Unconfirmed	A*24:51	Unconfirmed
A*24:02:09	Unconfirmed	A*24:02:59	Confirmed	A*24:06	Unconfirmed	A*24:52	Confirmed
A*24:02:10	Unconfirmed	A*24:02:60	Unconfirmed	A*24:07:01	Confirmed	A*24:53	Confirmed
A*24:02:11	Unconfirmed	A*24:02:61	Confirmed	A*24:07:02	Unconfirmed	A*24:54	Unconfirmed
A*24:02:12	Unconfirmed	A*24:02:62	Confirmed	A*24:08	Confirmed	A*24:55	Unconfirmed
A*24:02:13	Confirmed	A*24:02:63	Unconfirmed	A*24:09N	Confirmed	A*24:56	Confirmed
A*24:02:14	Confirmed	A*24:02:64	Unconfirmed	A*24:10:01	Confirmed	A*24:57	Confirmed
A*24:02:15	Unconfirmed	A*24:02:65	Confirmed	A*24:10:02	Unconfirmed	A*24:58	Confirmed
A*24:02:16	Confirmed	A*24:02:66	Unconfirmed	A*24:11N	Confirmed	A*24:59	Confirmed
A*24:02:17	Unconfirmed	A*24:02:67	Unconfirmed	A*24:13:01	Unconfirmed	A*24:60N	Unconfirmed
A*24:02:18	Confirmed	A*24:02:68	Confirmed	A*24:13:02	Confirmed	A*24:61	Unconfirmed
A*24:02:19	Confirmed	A*24:02:69	Unconfirmed	A*24:14:01:01	Confirmed	A*24:62	Confirmed
A*24:02:20	Unconfirmed	A*24:02:70	Unconfirmed	A*24:14:01:02	Unconfirmed	A*24:63	Unconfirmed
A*24:02:21	Unconfirmed	A*24:02:71	Unconfirmed	A*24:15	Unconfirmed	A*24:64	Confirmed
A*24:02:22	Confirmed	A*24:02:72	Confirmed	A*24:17	Confirmed	A*24:66	Unconfirmed
A*24:02:23	Confirmed	A*24:02:73	Confirmed	A*24:18	Unconfirmed	A*24:67	Unconfirmed
A*24:02:24	Confirmed	A*24:02:74	Unconfirmed	A*24:19	Unconfirmed	A*24:68	Unconfirmed
A*24:02:25	Confirmed	A*24:02:75	Unconfirmed	A*24:20	Confirmed	A*24:69	Unconfirmed
A*24:02:26	Confirmed	A*24:02:76	Unconfirmed	A*24:21:01	Confirmed	A*24:70	Confirmed
A*24:02:27	Confirmed	A*24:02:77	Unconfirmed	A*24:21:02	Unconfirmed	A*24:71	Confirmed
A*24:02:28	Unconfirmed	A*24:02:78	Unconfirmed	A*24:21:03	Confirmed	A*24:72	Confirmed
A*24:02:29	Confirmed	A*24:02:79	Unconfirmed	A*24:22	Confirmed	A*24:73	Unconfirmed
A*24:02:30	Confirmed	A*24:02:80	Unconfirmed	A*24:23	Confirmed	A*24:74:01	Unconfirmed
A*24:02:31	Confirmed	A*24:02:81	Unconfirmed	A*24:24	Confirmed	A*24:74:02	Unconfirmed
A*24:02:32	Unconfirmed	A*24:02:82	Unconfirmed	A*24:25	Confirmed	A*24:75	Unconfirmed
A*24:02:33	Unconfirmed	A*24:02:83	Unconfirmed	A*24:26	Confirmed	A*24:76	Unconfirmed
A*24:02:34	Unconfirmed	A*24:02:84	Unconfirmed	A*24:27	Unconfirmed	A*24:77	Unconfirmed
A*24:02:35	Confirmed	A*24:02:85	Confirmed	A*24:28	Confirmed	A*24:78	Unconfirmed
A*24:02:36	Unconfirmed	A*24:02:86	Unconfirmed	A*24:29	Confirmed	A*24:79	Unconfirmed
A*24:02:37	Confirmed	A*24:02:87	Unconfirmed	A*24:30	Confirmed	A*24:80	Unconfirmed
A*24:02:38	Unconfirmed	A*24:02:88	Confirmed	A*24:31	Unconfirmed	A*24:81	Confirmed
A*24:02:39	Unconfirmed	A*24:02:89	Unconfirmed	A*24:32	Confirmed	A*24:82	Unconfirmed
A*24:02:40	Unconfirmed	A*24:02:90	Confirmed	A*24:33	Confirmed	A*24:83N	Unconfirmed
A*24:02:41	Unconfirmed	A*24:02:91	Unconfirmed	A*24:34	Unconfirmed	A*24:84N	Unconfirmed



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: November 2022, Rev. No: 00

101.422-24/03 – including *Taq* polymerase  
101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>
A*24:85	Confirmed	A*24:134	Unconfirmed	A*24:181	Unconfirmed	A*24:229	Unconfirmed
A*24:86N	Unconfirmed	<b>A*24:135:01</b>	<b>Confirmed</b>	<b>A*24:182</b>	<b>Confirmed</b>	A*24:230	Unconfirmed
<b>A*24:87</b>	<b>Confirmed</b>	A*24:135:02	Unconfirmed	<b>A*24:183N</b>	<b>Confirmed</b>	<b>A*24:231</b>	<b>Confirmed</b>
A*24:88	Unconfirmed	A*24:136	Unconfirmed	<b>A*24:184</b>	<b>Confirmed</b>	A*24:232N	Unconfirmed
A*24:89	Unconfirmed	<b>A*24:137</b>	<b>Confirmed</b>	A*24:185N	Unconfirmed	<b>A*24:233</b>	<b>Confirmed</b>
<b>A*24:90:01N</b>	<b>Confirmed</b>	<b>A*24:138</b>	<b>Confirmed</b>	A*24:186	Unconfirmed	<b>A*24:234</b>	<b>Confirmed</b>
A*24:90:02N	Unconfirmed	A*24:139	Unconfirmed	A*24:187	Unconfirmed	<b>A*24:235</b>	<b>Confirmed</b>
A*24:91	Unconfirmed	A*24:140	Unconfirmed	<b>A*24:188</b>	<b>Confirmed</b>	A*24:236	Unconfirmed
A*24:92	Unconfirmed	A*24:141	Unconfirmed	A*24:189	Unconfirmed	A*24:237	Unconfirmed
<b>A*24:93</b>	<b>Confirmed</b>	A*24:142:01	Unconfirmed	A*24:190	Unconfirmed	<b>A*24:238</b>	<b>Confirmed</b>
A*24:94	Unconfirmed	A*24:142:02	Unconfirmed	A*24:191	Unconfirmed	A*24:239	Unconfirmed
<b>A*24:95</b>	<b>Confirmed</b>	A*24:143	Unconfirmed	<b>A*24:192</b>	<b>Confirmed</b>	A*24:240N	Unconfirmed
A*24:96	Unconfirmed	A*24:144	Unconfirmed	A*24:193	Unconfirmed	A*24:241	Unconfirmed
<b>A*24:97</b>	<b>Confirmed</b>	<b>A*24:145</b>	<b>Confirmed</b>	<b>A*24:194</b>	<b>Confirmed</b>	A*24:242	Unconfirmed
A*24:98	Unconfirmed	<b>A*24:146</b>	<b>Confirmed</b>	A*24:195	Unconfirmed	A*24:243	Unconfirmed
A*24:99	Unconfirmed	A*24:147	Unconfirmed	<b>A*24:196</b>	<b>Confirmed</b>	A*24:244	Unconfirmed
A*24:100	Unconfirmed	A*24:148	Unconfirmed	<b>A*24:197</b>	<b>Confirmed</b>	A*24:245	Unconfirmed
A*24:101	Unconfirmed	A*24:149	Unconfirmed	A*24:198	Unconfirmed	A*24:246	Unconfirmed
A*24:102	Unconfirmed	A*24:150	Unconfirmed	A*24:199	Unconfirmed	A*24:247	Unconfirmed
<b>A*24:103</b>	<b>Confirmed</b>	A*24:151	Unconfirmed	A*24:200	Unconfirmed	<b>A*24:248</b>	<b>Confirmed</b>
A*24:104	Unconfirmed	A*24:152	Unconfirmed	A*24:201	Unconfirmed	A*24:249	Unconfirmed
<b>A*24:105</b>	<b>Confirmed</b>	A*24:153	Unconfirmed	A*24:202	Unconfirmed	A*24:250	Unconfirmed
<b>A*24:106</b>	<b>Confirmed</b>	A*24:154	Unconfirmed	A*24:203	Unconfirmed	A*24:251	Unconfirmed
<b>A*24:107</b>	<b>Confirmed</b>	A*24:155N	Unconfirmed	A*24:204	Unconfirmed	<b>A*24:252N</b>	<b>Confirmed</b>
<b>A*24:108</b>	<b>Confirmed</b>	A*24:156	Unconfirmed	<b>A*24:205</b>	<b>Confirmed</b>	A*24:253	Unconfirmed
A*24:109	Unconfirmed	<b>A*24:157</b>	<b>Confirmed</b>	<b>A*24:206</b>	<b>Confirmed</b>	A*24:254	Unconfirmed
<b>A*24:110</b>	<b>Confirmed</b>	A*24:158N	Unconfirmed	<b>A*24:207:01</b>	<b>Confirmed</b>	<b>A*24:255</b>	<b>Confirmed</b>
A*24:111	Unconfirmed	<b>A*24:159</b>	<b>Confirmed</b>	A*24:207:02	Unconfirmed	A*24:256	Unconfirmed
A*24:112	Unconfirmed	<b>A*24:160</b>	<b>Confirmed</b>	A*24:208	Unconfirmed	A*24:257	Unconfirmed
<b>A*24:113</b>	<b>Confirmed</b>	A*24:161	Unconfirmed	A*24:209	Unconfirmed	A*24:258	Unconfirmed
A*24:114	Unconfirmed	A*24:162	Unconfirmed	A*24:210	Unconfirmed	A*24:259	Unconfirmed
<b>A*24:115</b>	<b>Confirmed</b>	A*24:163N	Unconfirmed	A*24:212	Unconfirmed	A*24:260	Unconfirmed
A*24:116	Unconfirmed	<b>A*24:164</b>	<b>Confirmed</b>	<b>A*24:213</b>	<b>Confirmed</b>	A*24:261	Unconfirmed
<b>A*24:117</b>	<b>Confirmed</b>	A*24:165	Unconfirmed	A*24:214	Unconfirmed	A*24:262	Unconfirmed
<b>A*24:118</b>	<b>Confirmed</b>	A*24:166	Unconfirmed	<b>A*24:215</b>	<b>Confirmed</b>	A*24:263	Unconfirmed
A*24:119	Unconfirmed	<b>A*24:167</b>	<b>Confirmed</b>	A*24:216	Unconfirmed	A*24:264	Unconfirmed
A*24:120	Unconfirmed	<b>A*24:168</b>	<b>Confirmed</b>	A*24:217	Unconfirmed	A*24:265	Unconfirmed
<b>A*24:121</b>	<b>Confirmed</b>	<b>A*24:169</b>	<b>Confirmed</b>	A*24:218	Unconfirmed	A*24:266	Unconfirmed
<b>A*24:122</b>	<b>Confirmed</b>	A*24:170	Unconfirmed	A*24:219	Unconfirmed	A*24:267	Unconfirmed
<b>A*24:123</b>	<b>Confirmed</b>	A*24:171	Unconfirmed	<b>A*24:220</b>	<b>Confirmed</b>	A*24:268	Unconfirmed
A*24:124	Unconfirmed	A*24:172:01	Unconfirmed	A*24:221	Unconfirmed	A*24:269	Unconfirmed
A*24:125	Unconfirmed	A*24:172:02	Unconfirmed	A*24:222N	Unconfirmed	A*24:270	Unconfirmed
A*24:126	Unconfirmed	<b>A*24:173</b>	<b>Confirmed</b>	A*24:223	Unconfirmed	A*24:271	Unconfirmed
A*24:127	Unconfirmed	A*24:174	Unconfirmed	A*24:224	Unconfirmed	A*24:272	Unconfirmed
<b>A*24:128</b>	<b>Confirmed</b>	A*24:175	Unconfirmed	<b>A*24:225:01</b>	<b>Confirmed</b>	A*24:273	Unconfirmed
<b>A*24:129</b>	<b>Confirmed</b>	A*24:176	Unconfirmed	<b>A*24:225:02</b>	<b>Confirmed</b>	A*24:274	Unconfirmed
A*24:130	Unconfirmed	A*24:177	Unconfirmed	A*24:226:01	Unconfirmed	<b>A*24:275</b>	<b>Confirmed</b>
A*24:131	Unconfirmed	A*24:178	Unconfirmed	A*24:226:02	Unconfirmed	<b>A*24:276</b>	<b>Confirmed</b>
<b>A*24:132N</b>	<b>Confirmed</b>	A*24:179	Unconfirmed	A*24:227	Unconfirmed	A*24:277	Unconfirmed
A*24:133	Unconfirmed	<b>A*24:180</b>	<b>Confirmed</b>	<b>A*24:228</b>	<b>Confirmed</b>	A*24:278N	Unconfirmed



0197

101.422-24/03 – including *Taq* polymerase  
 101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>
A*24:279	Unconfirmed	A*24:309	Unconfirmed	A*24:337	Unconfirmed	A*24:367	Unconfirmed
<b>A*24:280</b>	<b>Confirmed</b>	A*24:310:01	Unconfirmed	A*24:338	Unconfirmed	A*24:368	Unconfirmed
A*24:281	Unconfirmed	A*24:310:02	Unconfirmed	<b>A*24:339</b>	<b>Confirmed</b>	A*24:369	Unconfirmed
A*24:282	Unconfirmed	A*24:311	Unconfirmed	A*24:340	Unconfirmed	A*24:370N	Unconfirmed
A*24:283	Unconfirmed	A*24:312N	Unconfirmed	A*24:341	Unconfirmed	A*24:371	Unconfirmed
A*24:284	Unconfirmed	A*24:313:01	Unconfirmed	A*24:342	Unconfirmed	A*24:372	Unconfirmed
A*24:285	Unconfirmed	A*24:313:02	Unconfirmed	A*24:343	Unconfirmed	A*24:373	Unconfirmed
A*24:286	Unconfirmed	<b>A*24:314</b>	<b>Confirmed</b>	A*24:344	Unconfirmed	A*24:374	Unconfirmed
<b>A*24:287</b>	<b>Confirmed</b>	A*24:315	Unconfirmed	<b>A*24:345</b>	<b>Confirmed</b>	A*24:375	Unconfirmed
A*24:288	Unconfirmed	A*24:316	Unconfirmed	A*24:346	Unconfirmed	A*24:376	Unconfirmed
A*24:289	Unconfirmed	A*24:317	Unconfirmed	A*24:347	Unconfirmed	<b>A*24:377</b>	<b>Confirmed</b>
<b>A*24:290</b>	<b>Confirmed</b>	A*24:318	Unconfirmed	A*24:348	Unconfirmed		
A*24:291	Unconfirmed	A*24:319	Unconfirmed	A*24:349	Unconfirmed		
A*24:292	Unconfirmed	A*24:320	Unconfirmed	A*24:350	Unconfirmed		
<b>A*24:293</b>	<b>Confirmed</b>	A*24:321	Unconfirmed	A*24:351	Unconfirmed		
A*24:294Q	Unconfirmed	<b>A*24:322</b>	<b>Confirmed</b>	A*24:352	Unconfirmed		
A*24:295	Unconfirmed	A*24:323N	Unconfirmed	<b>A*24:353</b>	<b>Confirmed</b>		
A*24:296	Unconfirmed	<b>A*24:324</b>	<b>Confirmed</b>	A*24:354	Unconfirmed		
<b>A*24:297</b>	<b>Confirmed</b>	A*24:325	Unconfirmed	A*24:355	Unconfirmed		
A*24:298	Unconfirmed	A*24:326	Unconfirmed	<b>A*24:356</b>	<b>Confirmed</b>		
A*24:299	Unconfirmed	A*24:327	Unconfirmed	<b>A*24:357N</b>	<b>Confirmed</b>		
A*24:300	Unconfirmed	A*24:328	Unconfirmed	A*24:358	Unconfirmed		
A*24:301	Unconfirmed	A*24:329	Unconfirmed	A*24:359N	Unconfirmed		
<b>A*24:302</b>	<b>Confirmed</b>	A*24:330	Unconfirmed	A*24:360	Unconfirmed		
A*24:303N	Unconfirmed	<b>A*24:331</b>	<b>Confirmed</b>	A*24:361	Unconfirmed		
A*24:304	Unconfirmed	A*24:332	Unconfirmed	A*24:362	Unconfirmed		
A*24:305	Unconfirmed	A*24:333	Unconfirmed	A*24:363	Unconfirmed		
A*24:306	Unconfirmed	A*24:334	Unconfirmed	A*24:364	Unconfirmed		
<b>A*24:307</b>	<b>Confirmed</b>	A*24:335	Unconfirmed	A*24:365	Unconfirmed		
A*24:308	Unconfirmed	A*24:336	Unconfirmed	A*24:366	Unconfirmed		

<sup>1</sup>Allele status “confirmed” or “unconfirmed” as listed on the IMGT/HLA web page 2017-January-20, release 3.27.0, [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla).

### RESOLUTION IN HOMO- AND HETEROZYGOTES

Results file with resolution in HLA-A\*24 homo- and heterozygotes is available upon request.



0197

101.422-24/03 – including *Taq* polymerase  
101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information  
**SPECIFICITY TABLE**

**HLA-A\*24 SSP subtyping**

**Specificities and sizes of the PCR products of the 95+1 primer mixes used for HLA-A\*24 SSP subtyping**

Primer Mix	Size of spec. PCR product <sup>1</sup>	Size of control band <sup>2</sup>	Amplified HLA-A*24 alleles <sup>3</sup>	Other amplified HLA Class I alleles
1 <sup>7</sup>	180 bp	800 bp	*24:02:01:01-24:02:09, 24:02:11-24:02:122, 24:02:124-24:11N, 24:13:01-24:15, 24:17:01:01-24:32, 24:34-24:64, 24:66-24:210, 24:212-24:252N, 24:254-24:386, 24:388N-24:470, 24:472-24:554, 24:556N-24:578	*02:19, 02:804, 23:01:01:01-23:68, 23:70-23:86, 23:88-23:124, 33:19
2	245 bp	1070 bp	*24:03:01:01-24:03:04, 24:10:01:01-24:10:02, 24:18, 24:22, 24:33, 24:94, 24:125, 24:138, 24:167, 24:204, 24:207:01-24:207:02, 24:210, 24:289, 24:299-24:300, 24:315, 24:339-24:340, 24:374, 24:387, 24:441, 24:459, 24:461, 24:483, 24:488, 24:494-24:495, 24:506, 24:515, 24:524, 24:527, 24:540, 24:563, 24:570	*02:17:02:01-02:17:04, 02:108, 02:110, 02:268, 02:300, 02:303, 02:617, 02:657, 02:680, 02:963, 02:1054, 03:347, 11:139, 23:04, 23:83, 23:110, 29:07, 29:49, 31:29, 33:187, <b>B*18:27</b>
3	210 bp	800 bp	*24:02:01:01-24:05:02, 24:07:01:01-24:11N, 24:17:01:01-24:17:01:02, 24:19-24:21:03, 24:23, 24:25-24:50, 24:55-24:56:02, 24:58-24:63, 24:66-24:86N, 24:88-24:90:02N, 24:93, 24:95-24:106, 24:108-24:113, 24:115-24:132N, 24:134-24:137, 24:139-24:166, 24:168-24:187, 24:189-24:206, 24:208:01-24:210, 24:212-24:221, 24:223-24:226:02, 24:229-24:284, 24:286-24:288, 24:290, 24:292-24:295, 24:297-24:298, 24:300-24:303N, 24:305-24:314, 24:317-24:323N, 24:325-24:326, 24:328-24:338, 24:340-24:354, 24:356-24:380, 24:382-24:391, 24:393-24:411, 24:413-24:457, 24:459-24:470, 24:472-24:477, 24:479Q-24:480, 24:482-24:514N, 24:516-24:550, 24:552-24:554, 24:556N, 24:558-24:568N, 24:570-24:573, 24:575-24:578	*02:804, 11:139, 23:105, 23:113N, 33:19
4 <sup>5</sup>	220 bp	1070 bp	*24:06, 24:13:01-24:13:02, 24:18, 24:22, 24:24, 24:94, 24:138, 24:167, 24:188, 24:204, 24:207:01-24:207:02, 24:213, 24:228, 24:315, 24:339, 24:355, 24:381, 24:392, 24:515, 24:569	*02:17:02:01-02:17:04, 02:108, 02:110, 02:268, 02:300, 02:303, 02:617, 02:657, 02:680, 02:963, 02:1054, 03:347, 23:01:01:01-23:33, 23:35-23:68, 23:70-23:104, 23:106N-23:112, 23:114-23:124,



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: November 2022, Rev. No: 00



101.422-24/03 – including *Taq* polymerase  
 101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

				29:07, 29:49, 31:29, 33:187, <b>B*18:27</b>
<b>5</b>	175 bp	1070 bp	*24:02:01:01-24:04, 24:06-24:11N, 24:13:01-24:13:02, 24:17:01:01-24:23, 24:25-24:50, 24:54-24:56:02, 24:58- 24:63, 24:66-24:91, 24:93, 24:95- 24:113, 24:115-24:129, 24:131-24:137, 24:139-24:167, 24:169-24:187, 24:189-24:193, 24:195-24:198, 24:200-24:210, 24:212-24:221, 24:223-24:227, 24:229-24:290, 24:292, 24:294Q-24:295, 24:297-24:303N, 24:305-24:315, 24:317-24:318, 24:320-24:323N, 24:325-24:341, 24:343, 24:345-24:391, 24:393-24:394, 24:396N-24:407, 24:409-24:411, 24:413-24:457, 24:459-24:470, 24:472-24:480, 24:482-24:514N, 24:516-24:531, 24:533-24:550, 24:552-24:554, 24:556N, 24:558- 24:573, 24:575-24:578	*01:301Q, 02:17:02:01 <sup>w</sup> - 02:17:04 <sup>w</sup> , 02:804, 03:347, 11:139, 23:14:01-23:14:02, 23:104, 23:113N, 33:19
<b>6<sup>s</sup></b>	175 bp	1070 bp	*24:05:01-24:05:02, 24:24, 24:199, 24:342, 24:392, 24:395	*23:01:01:01-23:13, 23:15-23:68, 23:70-23:73, 23:75-23:103N, 23:105-23:112, 23:114-23:124, 29:07, 29:49, 31:29, 33:187, <b>B*18:27</b>
<b>7</b>	335 bp	1070 bp	*24:02:01:01-24:03:04, 24:05:01- 24:11N, 24:13:01-24:13:02, 24:17:01:01-24:18, 24:20:01:01-24:27, 24:29-24:43, 24:45N-24:50, 24:52, 24:54-24:56:02, 24:58-24:64, 24:66- 24:88, 24:90:01N-24:91, 24:93-24:108, 24:110-24:117, 24:119-24:128, 24:130-24:163N, 24:165-24:210, 24:212-24:254, 24:256-24:289, 24:292-24:295, 24:297-24:323N, 24:325-24:328, 24:330-24:372, 24:374-24:398, 24:400-24:403, 24:407-24:423, 24:425N-24:445N, 24:447Q-24:457, 24:459-24:470, 24:472-24:550, 24:552-24:554, 24:556N, 24:558-24:571, 24:573- 24:578	*23:01:01:01-23:26, 23:28-23:68, 23:70-23:74, 23:76-23:121, 23:123-23:124
<b>8<sup>d</sup></b>	75 bp	1070 bp	*24:04, 24:109	
<b>9</b>	225 bp	<b>800 bp</b>	*24:07:01:01-24:07:04, 24:19, 24:24, 24:112, 24:131, 24:288, 24:290, 24:294Q, 24:339, 24:347:01- 24:347:02, 24:387, 24:406, 24:453, 24:457, 24:477, 24:489, 24:510, 24:528, 24:541, 24:544, 24:566, 24:569, 24:574	*03:72, 11:88, 23:13, 29:37, 29:56, 30:01:01:01-30:01:21, 30:11:01-30:11:02, 30:14L-30:20, 30:23-30:26, 30:30-30:31, 30:35- 30:43, 30:48-30:49, 30:52-30:54, 30:56, 30:58-30:60, 30:62-30:63, 30:65, 30:72-30:75, 30:78N, 30:81-30:83, 30:86-30:89, 30:91- 30:98, 30:102, 30:104, 30:106, 30:109-30:116, 30:118, 30:120, 30:122-30:123N, 30:125-30:126,



**0197**

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: November 2022, Rev. No: 00

101.422-24/03 – including *Taq* polymerase  
 101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

				30:128-30:132N, 30:134-30:138, 30:140-30:143, 30:145N, 30:147-30:148, 30:154, 30:159, 30:161, 30:163-30:165, 30:167-30:168, 30:170-30:173, 30:176, 30:178N-30:181, 30:183-30:185, 30:187, 30:190-30:192, 30:194-30:197N, 30:199, 30:201-30:203, 68:45, 68:117
10 <sup>6</sup>	370 bp	800 bp	*24:02:01:01-24:02:04, 24:02:06-24:02:88, 24:02:90-24:02:99, 24:02:101-24:06, 24:08-24:11N, 24:13:01-24:13:02, 24:17:01:01-24:18, 24:20:01:01-24:23, 24:25-24:50, 24:52, 24:54-24:56:02, 24:58-24:64, 24:66-24:91, 24:93-24:107, 24:109-24:111, 24:113-24:117, 24:119-24:130, 24:132N-24:210, 24:212-24:251, 24:253-24:287, 24:289, 24:292-24:293, 24:295, 24:297-24:323N, 24:325-24:328, 24:330-24:338, 24:340-24:346, 24:349-24:386, 24:388N-24:403, 24:405, 24:407-24:452, 24:454-24:456N, 24:459-24:470, 24:472-24:476, 24:478-24:488, 24:490-24:509, 24:511-24:527, 24:529N-24:540, 24:542-24:543, 24:545-24:550, 24:552-24:554, 24:556N, 24:558-24:565, 24:567N-24:568N, 24:570-24:573, 24:575-24:578	*01:301Q, 02:10, 02:17:02:01-02:17:04, 02:39, 02:108, 02:110, 02:148, 02:242, 02:244, 02:268, 02:300, 02:303, 02:398, 02:453, 02:604, 02:617, 02:628, 02:630, 02:657, 02:680, 02:804, 02:963, 02:1025, 02:1054, 23:01:01:01-23:12, 23:14:01-23:21, 23:23-23:68, 23:70-23:74, 23:76-23:124, 31:29, 33:19, 33:187
11 <sup>7</sup>	200 bp	1070 bp	*24:08, 24:42, 24:89, 24:310:01-24:310:02, 24:342, 24:409	*02:76:01-02:76:03, 02:319, 02:666, 23:80, 30:22
	240 bp		*24:61, 24:307	*23:38N
12	235 bp	1070 bp	*24:25, 24:308	*23:05
13	160 bp	1070 bp	*24:02:01:01-24:02:155, 24:04-24:09N, 24:11N, 24:13:01-24:15, 24:17:01:01-24:17:01:02, 24:19-24:20:02, 24:23-24:32, 24:34-24:64, 24:66-24:74:02, 24:76-24:93, 24:95-24:109, 24:111-24:124, 24:126-24:137, 24:139-24:157, 24:159-24:166, 24:168-24:203, 24:205-24:206, 24:209, 24:212-24:218, 24:220-24:282, 24:284-24:288, 24:290-24:298, 24:301-24:314, 24:316-24:338, 24:341-24:348, 24:350-24:356, 24:358-24:373, 24:375-24:386, 24:388N-24:389N, 24:391-24:440, 24:442-24:458, 24:460:01:01-24:460:01:02, 24:462-24:470, 24:472-24:482, 24:484-24:487, 24:490-24:493, 24:496-24:498, 24:500-24:505, 24:507-24:513Q, 24:516-24:523, 24:525-24:526, 24:528-24:539, 24:541, 24:543-24:550, 24:552-24:554, 24:556N-24:561, 24:564-24:569, 24:571-24:578	*01:88:02-01:88:03, 01:236, 02:19, 02:36-02:37, 02:54, 02:255, 02:417, 02:468:01N, 02:723, 02:804, 02:848, 02:883, 02:949, 11:209, 23:01:01:01-23:02, 23:05-23:42, 23:44-23:68, 23:71-23:78, 23:80-23:82, 23:84N-23:107Q, 23:109, 23:111-23:119, 23:121-23:124, 33:19, 68:26, 68:65, 68:115, 68:131, 69:09



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: November 2022, Rev. No: 00

101.422-24/03 – including *Taq* polymerase  
 101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

14 <sup>4</sup>	95 bp 165 bp	1070 bp	*24:09N, 24:267 *24:251	*23:18
15 <sup>4</sup>	105 bp 385 bp	<b>800 bp</b>	*24:19, 24:44, 24:100, 24:109, 24:260 *24:14:01:01-24:15, 24:51, 24:53, 24:57, 24:92, 24:291, 24:296, 24:324, 24:458, 24:551, 24:555, 24:557	*11:325, 23:112, 23:122, 25:77 *02:46, 02:48, 02:70, 02:129, 02:571, 02:1050, 03:30, 03:152, 03:273, 11:325, 25:77, 25:81- 25:82, 30:07, 31:08, 32:05, 32:79, 33:21, 33:53, 68:249
16 <sup>4</sup>	85 bp	1070 bp	*24:17:01:01-24:17:01:02, 24:41, 24:208:01-24:208:02:02, 24:488, 24:499, 24:503, 24:535	*01:301Q, 03:347, 11:139, 23:53, 23:70, 29:07, 29:49
17	230 bp	1070 bp	*24:10:01:01-24:10:02, 24:46, 24:210, 24:300, 24:340, 24:377, 24:494- 24:495, 24:506, 24:528	*01:301Q, 11:139, 23:10:01, 23:110
18	275 bp	1070 bp	*24:02:01:02L, 24:450Q	
19 <sup>7</sup>	195 bp	1070 bp	*24:02:01:01-24:02:09, 24:02:11- 24:02:64, 24:02:66-24:02:122, 24:02:124-24:11N, 24:13:01-24:15, 24:17:01:01-24:32, 24:34-24:64, 24:66-24:210, 24:212-24:386, 24:388N-24:461, 24:463-24:470, 24:472-24:497, 24:499-24:554, 24:556N-24:558, 24:560-24:578	*02:19, 02:804, 23:01:01:01- 23:68, 23:70-23:86, 23:88-23:124, 33:19
20 <sup>6,7</sup>	470 bp	1070 bp	*24:11N	*01:04:01:01N-01:04:01:02N, 03:21N, 11:21N, 23:07N, 30:132N
21	155 bp 215 bp	<b>800 bp</b>	*24:31 *24:294Q	
22 <sup>4</sup>	125 bp 180 bp	<b>800 bp</b>	*24:27 *24:33, 24:387	*02:01:01:01-02:01:07, 02:01:09- 02:01:14Q, 02:01:17-02:01:19, 02:01:21-02:01:81, 02:01:83- 02:01:163, 02:01:165-02:01:196, 02:01:198-02:05:11, 02:05:13- 02:06:12, 02:06:14-02:07:03, 02:07:05-02:18, 02:20:01- 02:22:02, 02:24:01-02:64:02, 02:66-02:68, 02:70-02:97:02, 02:99:01-02:99:02, 02:101:01- 02:131:03, 02:133-02:134, 02:136-02:178, 02:180-02:304, 02:306-02:454, 02:456- 02:468:02N, 02:469 <sup>w</sup> , 02:470- 02:613, 02:615-02:624, 02:626- 02:650, 02:652-02:684, 02:686- 02:691N, 02:693-02:803N, 02:805Q-02:821, 02:823-02:828, 02:830:01-02:925, 02:928-02:966, 02:968-02:1060, 02:1062N- 02:1063N, 26:186, 66:36, 68:164, 69:01:01:01-69:09
23	190 bp	<b>800 bp</b>	*24:28, 24:30, 24:42, 24:89, 24:309, 24:379	*01:134, 01:229, 02:01:09, 02:03:11, 02:05:05, 02:06:07, 02:07:12, 02:50, 02:76:02- 02:76:03, 02:122, 02:243:02- 02:243:03, 02:528:02, 02:591:01,



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: November 2022, Rev. No: 00

101.422-24/03 – including *Taq* polymerase  
 101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

				03:09, 03:89:02, 03:108, 03:172, 03:198, 03:330N, 11:06, 11:18, 11:312, 23:12, 25:11, 26:03:01:01-26:03:01:02, 26:06, 26:21, 26:30, 26:78, 26:92, 26:111, 26:177, 26:193, 29:19, 29:48, 29:159, 32:08, 33:24, 33:184, 68:05, 68:15, 68:20, 68:255, 74:06, 74:21, 74:39
<b>24</b>	215 bp	<b>800 bp</b>	*24:24, 24:67, 24:145, 24:156, 24:191, 24:290, 24:392	*03:72, 11:88, 23:51, 26:16, 29:37, 29:56, 30:01:01:01-30:04:04, 30:06, 30:09:01:01-30:20, 30:23-30:30, 30:32-30:54, 30:56-30:59N, 30:61-30:78N, 30:80-30:132N, 30:134-30:149, 30:151, 30:153-30:165, 30:167-30:176, 30:178N-30:185, 30:187-30:203, 31:210, 32:07, 33:119, 68:45, 68:117
	240 bp		*24:19, 24:28, 24:44, 24:89, 24:290, 24:379, 24:406, 24:424	*02:76:01-02:76:03, 02:319, 02:666, 03:72, 11:88, 30:01:01:01-30:01:21, 30:11:01-30:11:02, 30:13-30:20, 30:23-30:24, 30:26, 30:30-30:31, 30:35-30:44, 30:46, 30:48-30:49, 30:52-30:54, 30:56, 30:58-30:60, 30:62-30:63, 30:65, 30:71-30:75, 30:78N, 30:81-30:83, 30:86-30:87, 30:89, 30:91-30:98, 30:102, 30:104, 30:106, 30:109-30:116, 30:118, 30:120, 30:122-30:123N, 30:125-30:126, 30:128-30:132N, 30:134-30:138, 30:140-30:143, 30:145N, 30:147-30:148, 30:154, 30:157, 30:159, 30:161, 30:163-30:165, 30:167-30:168, 30:170-30:173, 30:176, 30:178N-30:181, 30:183-30:185, 30:187, 30:190-30:192, 30:194-30:197N, 30:199, 30:201-30:203, 31:210, 33:119, 68:45, 68:117
<b>25</b>	205 bp	1070 bp	*24:13:01-24:13:02, 24:18, 24:24, 24:56:01-24:56:02, 24:94, 24:177, 24:188, 24:207:01-24:207:02, 24:228, 24:315, 24:355, 24:367, 24:381, 24:392, 24:515, 24:569	*02:17:02:01-02:17:04, 02:108, 02:110, 02:268, 02:300, 02:303, 02:617, 02:657, 02:1054, 03:347, 23:01:01:01-23:01:37, 23:03:01-23:65, 23:67-23:68, 23:70-23:104, 23:106N-23:112, 23:114-23:124, 29:07, 29:49, 31:29, 33:187, <b>B*18:27</b>
	230 bp		*24:18, 24:204, 24:213	*03:347
<b>26<sup>4</sup></b>	90 bp	<b>800 bp</b>	*24:96, 24:256	
	220 bp		*24:22, 24:160, 24:299, 24:478	
<b>27<sup>4,7</sup></b>	80 bp	<b>800 bp</b>	*24:32	*23:36, 25:77, 32:05, 32:79
	370 bp		*24:14:01:01-24:14:01:04, 24:324	*02:46, 02:48, 02:70, 02:129, 02:571, 02:1050



**0197**

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: November 2022, Rev. No: 00

101.422-24/03 – including *Taq* polymerase  
101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

<b>28</b> <sup>4,6,7</sup>	75 bp 125 bp 155 bp	<b>800 bp</b>	*24:155N *24:266 *24:35, 24:264, 24:441	*02:691N  *01:306, 11:193
<b>29</b> <sup>4,6,7</sup>	75 bp 120 bp  200 bp	<b>800 bp</b>	*24:155N *24:265, 24:271  *24:08, 24:29, 24:42, 24:89, 24:309- 24:310:02, 24:342, 24:359N	*02:691N *01:45, 03:78, 11:108, 23:92, 23:96, 30:201, 36:12 *02:76:01-02:76:03, 02:319, 02:666, 23:80, 23:100, 30:22
<b>30</b> <sup>4</sup>	125 bp  200 bp	<b>800 bp</b>	*24:21:01-24:21:03, 24:208:01- 24:208:02:02, 24:489, 24:499, 24:562  *24:59, 24:190, 24:210, 24:229, 24:285, 24:395, 24:503	*01:301Q, 03:347, 11:139, 23:03:01-23:03:02:02, 23:70, 23:83, 29:07, 29:49, 31:29, 33:187, <b>B*18:27</b> *01:301Q, 11:139
<b>31</b>	155 bp 235 bp	<b>800 bp</b>	*24:37 *24:04, 24:109, 24:119, 24:129	*30:188 *01:02:01:01-01:02:02, 01:20, 01:188, 01:190, 01:307, 01:412, 26:16, 29:37, 29:56, 30:57, 30:90
<b>32</b>	225 bp	1070 bp	*24:15, 24:41, 24:51, 24:92, 24:235, 24:499, 24:504, 24:551, 24:557	*01:01:01:01-01:01:01:65, 01:01:67- 01:01:101, 01:01:103-01:01:130, 01:01:132-01:04:01:02N, 01:06- 01:33, 01:35-01:37:01:02, 01:39- 01:41, 01:43-01:71, 01:73-01:101, 01:103-01:127, 01:129-01:138, 01:140:01-01:153, 01:155-01:166, 01:168-01:199, 01:201-01:220, 01:222-01:243, 01:245-01:266:02, 01:268-01:283, 01:285N-01:379N, 01:381-01:389, 01:391-01:417N, 01:419, 11:27, 11:38-11:39, 11:94, 11:209, 11:271, 11:326, 23:31, 23:45, 23:55, 25:36, 25:59, 25:65, 26:29, 26:49, 26:205, 32:13, 66:10, <b>B*07:64,</b> <b>B*15:12:01-15:12:03, B*15:19,</b> <b>B*15:270, B*15:298, B*15:304N</b>
<b>33</b> <sup>4</sup>	100 bp	1070 bp	*24:02:03Q, 24:39, 24:139	*01:01:38L, 03:01:96, 11:01:98, 30:02:25
<b>34</b>	195 bp	<b>800 bp</b>	*24:36N	
<b>35</b>	180 bp 205 bp	1070 bp	*24:142:01- 24:142:02 *24:45N, 24:88	
<b>36</b> <sup>4,7</sup>	115 bp  220 bp 245 bp	1070 bp	*24:47, 24:124  *24:192 *24:232N	*23:114, 31:07, 31:10, <b>B*44:540,</b> <b>B*51:290, B*52:87, B*53:58</b> <b>B*49:27</b>
<b>37</b>	210 bp	1070 bp	*24:48N, 24:54	
<b>38</b>	145 bp 170 bp 230 bp	<b>800 bp</b>	*24:49:01-24:49:02 *24:137 *24:126	
<b>39</b> <sup>4</sup>	75 bp 210 bp	<b>800 bp</b>	*24:185N *24:50	*02:129, 02:1050, 11:325, 25:81- 25:82, 68:249



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: November 2022, Rev. No: 00

101.422-24/03 – including *Taq* polymerase  
 101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

40 <sup>4</sup>	95 bp	1070 bp	*24:02:03Q	*01:01:38L, 03:01:96, 11:01:98, 30:02:25
	225 bp		*24:08, 24:20:01:01-24:20:02, 24:88, 24:337, 24:342	
41	200 bp	1070 bp	*24:26, 24:62, 24:314	*01:39, 01:145, 23:45, 26:29, 26:49, 31:05, 32:13, 33:10, 66:10
	240 bp		*24:118, 24:132N	
42 <sup>4</sup>	95 bp	1070 bp	*24:312N	
	160 bp		*24:22, 24:160, 24:276, 24:299, 24:478	*02:262, 02:547, 02:700, 02:910
	190 bp		*24:24, 24:67, 24:169, 24:290, 24:392	*26:16, 30:163, 33:119, 68:45, 68:117, <b>C*04:81</b>
43	160 bp	<b>800 bp</b>	*24:43, 24:159, 24:303N	*23:81
44	250 bp	<b>800 bp</b>	*24:51, 24:57, 24:92, 24:120, 24:458, 24:551, 24:557	*01:01:01:01-01:01:65, 01:01:67-01:04:01:02N, 01:06-01:19, 01:21-01:33, 01:35-01:65, 01:67:01-01:71, 01:74-01:101, 01:103-01:129, 01:131-01:166, 01:168-01:199, 01:201-01:243, 01:245-01:266:02, 01:268-01:283, 01:285N-01:300, 01:302-01:379N, 01:381-01:389, 01:391-01:417N, 01:419, 03:18, 03:97, 03:122, 03:135, 03:167, 11:27, 11:38-11:39, 11:94, 11:209, 11:271, 11:326, 25:36, 25:59, 25:65, 26:29, 26:49, 26:205, 29:03, 29:33, 30:75, 31:05, 31:200, 32:13, 33:10, 66:10, 68:26, 68:65, 68:115, 68:131, 80:01:01:01-80:09N
45 <sup>7.8</sup>	150 bp	1070 bp	*24:276	
	200 bp		*24:113, 24:370N	
	240 bp		*24:14:01:01-24:14:01:04, 24:52, 24:132N, 24:233, 24:291, 24:324	*01:20, 01:66, 01:73, 01:130, 02:19, 02:36-02:37, 02:54, 02:255, 02:417, 02:723, 02:848, 02:883, 02:949, 25:36, 25:65, 26:29, 26:49, 26:205, 66:10, 69:09, <b>B*07:64<sup>w</sup>, B*15:12:01<sup>w</sup>-15:12:03<sup>w</sup>, B*15:19<sup>w</sup>, B*15:270<sup>w</sup>, B*15:298<sup>w</sup>, B*15:304N<sup>w</sup></b>
46 <sup>4</sup>	110 bp	1070 bp	*24:15, 24:41, 24:51, 24:92, 24:235, 24:504, 24:557	*01:88:02-01:88:03, 01:236, 02:50, 02:73, 02:93:01-02:93:02, 02:122, 02:156, 02:172, 02:279, 02:594, 02:631, 02:651, 02:932, 02:952, 11:119:01-11:119:02, 11:209, 23:31, 23:45, 23:55, 26:10, 32:28, 32:66, 32:158, 68:02:01:01-68:02:23, 68:15, 68:18N, 68:25, 68:27:01-68:28, 68:31, 68:34, 68:40, 68:44, 68:48-68:49N, 68:51, 68:53-68:54, 68:60-68:62, 68:64, 68:67, 68:74, 68:77-68:78, 68:80-68:82, 68:86, 68:92, 68:97, 68:110, 68:119:01-68:119:02, 68:124-68:125,



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: November 2022, Rev. No: 00

101.422-24/03 – including *Taq* polymerase  
 101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

				68:128, 68:138, 68:147, 68:153, 68:160, 68:163, 68:169-68:170, 68:174, 68:178, 68:184, 68:186- 68:187, 68:193, 68:198, 68:201, 68:216N, 68:219, 68:225, 68:236N-68:237, 68:242, 68:250, 68:262, 68:272, 68:274-68:275, 68:278, 68:291-68:292N, 68:294, 69:04, <b>B*07:136:02,</b> <b>B*40:323:02, B*44:59:02,</b> <b>B*44:136, B*51:136, B*53:60,</b> <b>C*06:209:02, C*07:204:01,</b> <b>C*07:482, C*12:37</b>
<b>47</b>	195 bp  410 bp	<b>800 bp</b>	*24:18, 24:56:01-24:56:02, 24:123, 24:177, 24:355, 24:367, 24:381 *24:26	*03:347  *03:30, 03:152, 03:273, 11:325, 30:07, 31:08, 32:05, 32:79, 33:53
<b>48<sup>5</sup></b>	195 bp	1070 bp	*24:24, 24:71, 24:315, 24:392, 24:527, 24:569	*23:01:01:01-23:23, 23:25-23:33, 23:35-23:56, 23:58-23:65, 23:67- 23:68, 23:70-23:103N, 23:105- 23:112, 23:114-23:124, 29:07, 29:49, 31:29, 33:187, <b>B*18:27</b>
<b>49</b>	165 bp 250 bp	1070 bp	*24:159 *24:23, 24:220	<b>B*18:27</b>
<b>50</b>	165 bp 225 bp 260 bp	1070 bp	*24:251 *24:34, 24:252N, 24:270 *24:163N, 24:255	*23:27
<b>51</b>	165 bp 215 bp	<b>800 bp</b>	*24:140 *24:38, 24:337	
<b>52<sup>4,7</sup></b>	75 bp 210 bp 240 bp	<b>800 bp</b>	*24:293 *24:264, 24:441 *24:40N	*11:359 *01:306, 11:193
<b>53<sup>4</sup></b>	125 bp 160 bp 230 bp	1070 bp	*24:158N *24:303N *24:55, 24:315, 24:374	
<b>54<sup>7</sup></b>	175 bp 285 bp	1070 bp	*24:58, 24:169, 24:359N *24:248	<b>C*04:81</b> <b>C*03:231, C*04:52, C*04:55,</b> <b>C*04:405, C*14:10, C*14:46:02</b>
<b>55<sup>4</sup></b>	80 bp 240 bp 275 bp	1070 bp	*24:205 *24:60N, 24:302, 24:307 *24:173	*23:40
<b>56</b>	270 bp	1070 bp	*24:63	*26:169, 68:92
<b>57</b>	135 bp	1070 bp	*24:64	*02:736, <b>C*06:209:02, C*12:37</b>
<b>58</b>	200 bp	1070 bp	*24:66, 24:96, 24:146, 24:308, 24:333	*23:46, 30:75
<b>59</b>	240 bp 280 bp	1070 bp	*24:68, 24:143 *24:127, 24:215, 24:288	*23:78
<b>60</b>	140 bp 210 bp 275 bp	<b>800 bp</b>	*24:250 *24:183N, 24:270 *24:69	
<b>61<sup>4,6</sup></b>	105 bp 165 bp 280 bp	<b>800 bp</b>	*24:70 *24:323N *24:127, 24:141, 24:288	



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: November 2022, Rev. No: 00

101.422-24/03 – including *Taq* polymerase  
101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

<b>62<sup>4</sup></b>	120 bp 180 bp 280 bp	<b>800 bp</b>	*24:72, 24:91 *24:275 *24:297	*01:243, 02:106, 02:145
<b>63</b>	135 bp	1070 bp	*24:73, 24:157, 24:453	*23:16, 33:180, 68:107 *03:170, <b>B*13:153, B*18:38, B*40:197, B*57:68</b>
<b>64<sup>4,7</sup></b>	115 bp	1070 bp	*24:124	*31:07, 31:10
<b>65<sup>4</sup></b>	80 bp 155 bp 180 bp 235 bp	1070 bp	*24:75 *24:194 *24:275 *24:90:01N-24:90:02N	*01:267  *02:88N, 02:622N, 02:643N <sup>?</sup>
<b>66</b>	155 bp	<b>800 bp</b>	*24:77	*11:01:76, 11:106, 23:28, 32:05
<b>67<sup>4</sup></b>	90 bp 230 bp	1070 bp	*24:249, 24:267, 24:544 *24:79	*23:18, 23:88
<b>68<sup>7</sup></b>	220 bp 280 bp	<b>800 bp</b>	*24:143, 24:353 *24:78, 24:141, 24:196	
<b>69<sup>4</sup></b>	115 bp 200 bp 265 bp	1070 bp	*24:80, 24:225:01-24:225:02 *24:370N *24:184, 24:240N	<b>C*04:302, C*14:14</b>
<b>70<sup>4</sup></b>	110 bp 200 bp 255 bp	1070 bp	*24:134 *24:96, 24:146 *24:81, 24:356	
<b>71<sup>4</sup></b>	120 bp 205 bp 250 bp	<b>800 bp</b>	*24:128, 24:269 *24:183N, 24:199 *24:82, 24:280	*23:29  *29:13, 31:07-31:08, 31:10, 32:42, 32:97
<b>72<sup>4,7</sup></b>	120 bp 150 bp	1070 bp	*24:83N, 24:265-24:266 *24:354	
<b>73<sup>4</sup></b>	100 bp 170 bp	1070 bp	*24:84N *24:131, 24:138, 24:188, 24:218, 24:515	*02:17:02:01-02:17:04, 02:108, 02:110, 02:268, 02:300, 02:303, 02:617, 02:657, 02:680, 02:963, 02:1054
<b>74</b>	155 bp 195 bp	1070 bp	*24:180, 24:323N *24:85, 24:197	
<b>75</b>	145 bp 190 bp 285 bp	1070 bp	*24:180 *24:345 *24:86N, 24:196, 24:215	*23:78
<b>76<sup>7</sup></b>	175 bp 255 bp	1070 bp	*24:76, 24:263 *24:98, 24:220	<b>B*18:27</b>
<b>77<sup>4</sup></b>	115 bp 145 bp 210 bp	<b>800 bp</b>	*24:331 *24:122 *24:06, 24:87, 24:138, 24:167, 24:285, 24:289, 24:339, 24:381	*02:680, 02:963, 23:02, 23:66
<b>78</b>	140 bp	<b>800 bp</b>	*24:57, 24:92, 24:120, 24:458, 24:557	*01:88:02-01:88:03, 01:236, 02:50, 02:73, 02:122, 02:156, 02:245, 02:334, 02:338, 02:890, 02:952, 02:985, 03:17:01, 03:171, 11:119:01-11:119:02, 11:209, 26:10, 29:101:01-29:101:02, 30:61, 30:74, 31:67-31:68, 32:28, 32:66, 32:158, 33:32:01, 33:152, 68:01:01:01-68:01:21, 68:01:23-68:01:29, 68:01:31-68:43:02,



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: November 2022, Rev. No: 00



101.422-24/03 – including *Taq* polymerase  
 101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

				68:45-68:82, 68:84-68:90, 68:92-68:104:02, 68:106-68:122, 68:124-68:139, 68:141-68:144, 68:146-68:245N, 68:247, 68:249-68:258, 68:260-68:292N, 68:294
79	195 bp 250 bp	1070 bp	*24:182 *24:14:01:01-24:14:01:04, 24:93, 24:114, 24:233, 24:324	*23:76 *01:20, 01:66, 01:130, 02:19, 02:36-02:37, 02:54, 02:255, 02:417, 02:723, 02:848, 02:883, 02:949, 69:09
80	170 bp 220 bp	1070 bp	*24:140, 24:142:01-24:142:02 *24:95	
81 <sup>4</sup>	100 bp 215 bp	1070 bp	*24:139 *24:97, 24:133, 24:377	
82	185 bp 230 bp 285 bp	1070 bp	*24:99, 24:130 *24:125, 24:302, 24:472 *24:248	*23:40 <b>C*03:231, C*04:52, C*04:55, C*04:405, C*14:10, C*14:46:02 C*04:302, C*14:14</b>
83 <sup>4</sup>	125 bp 270 bp	<b>800 bp</b>	*24:111, 24:225:01-24:225:02 *24:101, 24:173, 24:240N	
84 <sup>4,7</sup>	105 bp 210 bp 290 bp	1070 bp	*24:103, 24:331 *24:107 *24:102, 24:287, 24:566	
85	145 bp 210 bp	1070 bp	*24:117 *24:104	*03:30, 03:152, 03:273, 23:64, 32:05, 32:79
86	190 bp 255 bp	1070 bp	*24:121, 24:182 *24:105, 24:222N, 24:356	*23:76, 23:97
87 <sup>4</sup>	90 bp	1070 bp	*24:17:01:01-24:17:01:02, 24:41, 24:62, 24:106, 24:208:01-24:208:02:02, 24:330, 24:488, 24:499, 24:503, 24:535 *24:110 *24:136, 24:197	*01:301Q, 03:347, 11:139, 23:31, 23:45, 23:53, 23:70, 29:07, 29:49, 31:29, 33:187
88 <sup>4</sup>	120 bp 190 bp 75 bp 170 bp 420 bp	1070 bp	*24:185N *24:116, 24:137 *24:352	
89 <sup>4</sup>	75 bp	1070 bp	*24:07:01:01-24:07:04, 24:108, 24:112, 24:131, 24:288, 24:339, 24:347:01-24:347:02, 24:387, 24:453, 24:457, 24:477, 24:489, 24:510, 24:528, 24:541, 24:544, 24:566, 24:569, 24:574 *24:192 *24:112, 24:414	*23:13 <b>B*49:27 B*13:102, B*44:322, B*51:129</b>
90 <sup>4</sup>	220 bp 270 bp 100 bp 180 bp 265 bp 290 bp	1070 bp	*24:115, 24:206 *24:168 *24:322 *24:234, 24:287, 24:339, 24:347:02	*23:124 *23:47
91 <sup>4</sup>	80 bp	1070 bp	*24:135:01-24:135:02, 24:357N, 24:524 *24:238	*23:45, 23:73
92	270 bp 150 bp 185 bp	1070 bp	*24:354 *24:144, 24:263, 24:268	



0197

101.422-24/03 – including *Taq* polymerase  
 101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

<b>93</b>	170 bp	1070 bp	*24:74:01-24:74:02	*23:102, <b>B*13:90, B*37:90,</b> <b>B*44:63<sup>w</sup>, B*57:105</b>
	245 bp		*24:280	*32:97
	270 bp		*24:112, 24:414	<b>B*13:102, B*44:322, B*51:129</b>
<b>94<sup>4</sup></b>	105 bp	<b>800 bp</b>	*24:206	
	190 bp		*24:345	
	220 bp		*24:278N	
	265 bp		*24:322	*23:124
<b>95<sup>4,9</sup></b>	115 bp	1070 bp	*24:269	
	145 bp		*24:231, 24:250	
	260 bp		*24:163N	
	355 bp		*24:14:01:01-24:14:01:04, 24:291, 24:410	*02:81, 02:87, 02:112, 02:124, 02:129, 02:136, 02:571, 23:82
<b>96<sup>10</sup></b>	<b>Negative Control</b>			

<sup>1</sup>Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-A\*24 SSP typings.

When the primers in a primer mix can give rise to HLA-specific PCR products of more than one length this is indicated if the size difference is more than 20 base pairs. Size differences of 20 base pairs or less are not given. For high resolution SSP kits, the alleles listed are specified according to amplicon length.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherit feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

<sup>2</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

<sup>3</sup>For several HLA Class I alleles 1st and/or 4th exon(s) and beyond, as well as intron nucleotide sequences, are not available. In these instances it is not known whether some of the primers of the SSP sets are completely matched with the target sequences or not. Assumption is made that unknown sequences in these regions are conserved within allelic groups.

<sup>4</sup>HLA-specific PCR products shorter than 125 base pairs have a lower intensity and are less sharp than longer PCR products.

<sup>5</sup>Primer mixes 4, 6 and 48 may give rise to a lower yield of HLA-specific PCR product than the other A\*24 primer mixes.

<sup>6</sup>Primer mixes 10, 20, 28, 29 and 61 have a tendency to giving rise to primer oligomer formation.

<sup>7</sup>Primer mixes 1, 11, 19, 20, 27, 28, 29, 36, 45, 52, 54, 64, 68, 72, 76 and 84 may have tendencies of unspecific amplifications.

<sup>8</sup>Primer mix 45 may give rise to a long fragment of approx. 500 bp in some HLA-A alleles. This band should not be considered in the interpretation of HLA-A\*24 typings.

<sup>9</sup>In primer mix 95 the positive control band may be weaker than for other HLA-A\*24 primer mixes.

<sup>10</sup>Primer mix 96 contains a negative control, which will amplify a majority of HLA amplicons as well as the amplicons generated by the control primer pairs matching the human growth hormone gene. HLA-specific PCR product sizes range from 75 to 200 base pairs and the PCR product generated by the HGH positive control primer pair is 200 base pairs.

#### Abbreviations

'w', might be weakly amplified.

'?', nucleotide sequence information not available for the primer matching sequence.



**0197**

For *In Vitro* Diagnostic Use

MA123 v02 SSP PI Template

Date: November 2022, Rev. No: 00

101.422-24/03 – including *Taq* polymerase  
101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

## PRIMER SPECIFICATION

Well No.	1	2	3	4	5	6	7	8	9	10	11	12
Length of spec. PCR product	180	245	210	220	175	175	335	75	225	370	200	235
Length of int. pos. control <sup>1</sup>	800	1070	800	1070	1070	1070	1070	1070	800	800	1070	1070
5'-primer(s) <sup>2</sup>	678 5'-AgA 3'	368 5'-gTT 3'	368 5'-gTT 3'	368 5'-gTT 3'	368 5'-gTT 3'	368 5'-gTT 3'	312 5'-ATT 3'	265 5'-CAg 3'	98 5'-CTC 3'	282 5'-CAC 3'	98 5'-CTC 3'	28 5'-TCg 3'
							315 5'-gCC 3'			282 5'-CAT 3'		
							317 5'-gCT 3'					
3'-primer(s) <sup>3</sup>	819 5'-ggT 3'	570 5'-CAC 3'	539 5'-TCT 3'	538 5'-CAA 3'	502 5'-CTT 3'	502 5'-CTg 3'	368 5'-CAA 3'	299 5'-TCg 3'	282 5'-gAC 3'	368 5'-CAA 3'	256 5'-CCC 3'	92 5'-AAC 3'
	819 5'-ggA 3'			538 5'-CCA 3'					282 5'-gAC 3'		293 5'-ggA 3'	
				538 5'-CAg 3'							303 5'-AgT 3'	
				555 5'-CCA 3'								
Well No.	1	2	3	4	5	6	7	8	9	10	11	12

Well No.	13	14	15	16	17	18	19	20	21	22	23	24
Length of spec. PCR product	160	95	105	85	230	275	195	470	155	125	190	215
Length of int. pos. control <sup>1</sup>	1070	1070	800	1070	1070	1070	1070	1070	800	800	800	800
5'-primer(s) <sup>2</sup>	453 5'-AAA 3'	678 5'-AgA 3'	265 5'-CAg 3'	368 5'-gTT 3'	368 5'-gTT 3'	2 <sup>nd</sup>   5'-CgA 3'	678 5'-A gA 3'	3 <sup>rd</sup>   5'-ATA 3'	144 5'-gCC 3'	485 5'-CAg 3'	144 5'-gCC 3'	98 5'-CTC 3'
	453 5'-AAA 3'									666 5'-gAA 3'		
3'-primer(s) <sup>3</sup>	570 5'-CCg 3'	728 5'-CCT 3'	320 5'-AgA 3'	413 5'-gCC 3'	553 5'-CTg 3'	570 5'-CCg 3'	831 5'-TCC 3'	621 5'-ggg 3'	259 5'-CTg 3'	570 5'-CCg 3'	292 5'-gTg 3'	270 5'-ACA 3'
	570 5'-CAg 3'	742 5'-CTA 3'	341 5'-CgT 3'		559 5'-CCg 3'				320 5'-AgC 3'	806 5'-CCg 3'	292 5'-gTg 3'	299 5'-CCA 3'
	573 5'-AgT 3'	800 5'-ACC 3'	368 5'-CAT 3'		559 5'-CCg 3'							
Well No.	13	14	15	16	17	18	19	20	21	22	23	24



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: November 2022, Rev. No: 00

101.422-24/03 – including *Taq* polymerase  
101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

Well No.	25	26	27	28	29	30	31	32	33	34	35	36
Length of spec.	205	90	80	75	75	125	155	225	100	195	180	115
PCR product	230	220	370	125	120	200	235				205	220
				155	200							245
Length of int.	1070	<b>800</b>	<b>800</b>	<b>800</b>	<b>800</b>	<b>800</b>	<b>800</b>	1070	1070	<b>800</b>	1070	1070
pos. control <sup>1</sup>												
5'-primer(s) <sup>2</sup>	368 5'-gTT 3'	368 5'-gTT 3'	265 5'-CAg 3'	98 5'-CTC 3'	98 5'-CTC 3'	368 5'-gTT 3'	98 5'-CTC 3'	385 5'-ggC 3'	368 5'-gTT 3'	98 5'-CTC 3'	98 5'-CTT 3'	114 5'-Cgg 3'
				662 5'-CCg 3'	692 5'-ggC 3'				650 5'-CCC 3'		105 5'-Tgg 3'	140 5'-CAC 3'
				695 5'-CTC 3'	704 5'-TgT 3'						124 5'-gCC 3'	242 5'-gCT 3'
				741 5'-g.C 3'	741 5'-g.C 3'						124 5'-gCA 3'	243 5'-CCT 3'
3'-primer(s) <sup>3</sup>	527 5'-CCT 3'	419 5'-CgA 3'	302 5'-ggC 3'	214 5'-CCA 3'	247 5'-TC 3'	453 5'-TCg 3'	212 5'-gCA 3'	570 5'-CCg 3'	427 5'-gTA 3'	250 5'-CA 3'	265 5'-CCC 3'	317 5'-ggA 3'
	539 5'-TCA 3'	545 5'-AgA 3'	355 5'-gAC 3'	777 5'-gCA 3'	265 5'-CCg 3'	453 5'-TCA 3'	289 5'-AgC 3'		427 5'-gTT 3'			
	555 5'-CCA 3'				777 5'-gCA 3'	527 5'-CCg 3'	299 5'-TCg 3'		705 5'-TCT 3'			
Well No.	25	26	27	28	29	30	31	32	33	34	35	36

Well No.	37	38	39	40	41	42	43	44	45	46	47	48
Length of spec.	210	145	75	95	200	95	160	250	150	110	195	195
PCR product		170	210	225	240	160			200		410	
		230				190			240			
Length of int.	1070	<b>800</b>	<b>800</b>	1070	1070	1070	<b>800</b>	<b>800</b>	1070	1070	<b>800</b>	1070
pos. control <sup>1</sup>												
5'-primer(s) <sup>2</sup>	368 5'-gTT 3'	77 5'-CTT 3'	98 5'-CTA 3'	28 5'-TCg 3'	370 5'-TTA 3'	98 5'-CTC 3'	368 5'-gTT 3'	355 5'-CCA 3'	98 5'-CTC 3'	385 5'-ggC 3'	28 5'-TCC 3'	368 5'-gTT 3'
		134 5'-CCA 3'	232 5'-AgT 3'	650 5'-CCC 3'	375 5'-TgA 3'	418 5'-AgT 3'		363 5'-ATA 3'	360 5'-CAC 3'		115 5'-ggT 3'	
		160 5'-ACT 3'			404 5'-CCA 3'				362 5'-gAg 3'		368 5'-gTT 3'	
					414 5'-CAg 3'				362 5'-gAg 3'			
									375 5'-TgA 3'			
									410 5'-gTg 3'			
3'-primer(s) <sup>3</sup>	532 5'-CTA 3'	265 5'-CCC 3'	265 5'-CCC 3'	81 5'-gAT 3'	570 5'-CCg 3'	153 5'-ACT 3'	485 5'-CA 3'	570 5'-CCg 3'	209 5'-gCC 3'	453 5'-TCT 3'	265 5'-CCC 3'	524 5'-CAC 3'
	544 5'-ggg 3'			705 5'-TCT 3'		209 5'-gCC 3'	488 5'-CCT 3'		256 5'-CTA 3'		527 5'-CCT 3'	524 5'-CAC 3'
						239 5'-gCT 3'	490 5'-AgT 3'		570 5'-CCg 3'			
						259 5'-gTT 3'						
						545 5'-AgA 3'						
Well No.	37	38	39	40	41	42	43	44	45	46	47	48



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: November 2022, Rev. No: 00

101.422-24/03 – including *Taq* polymerase  
101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

Well No.	49	50	51	52	53	54	55	56	57	58	59	60
Length of spec. PCR product	165	165	165	75	125	175	80	270	135	200	240	140
		225	215	210	160	285	240				280	210
		260		240	230		275					275
Length of int. pos. control <sup>1</sup>	1070	1070	<b>800</b>	<b>800</b>	1070	1070	1070	1070	1070	1070	1070	<b>800</b>
5'-primer(s) <sup>2</sup>	368 5'-gTT 3'	98 5'-CTC 3'	90 5'-AgC 3'	506 5'-gCA 3'	368 5'-gTT 3'	98 5'-CTC 3'	98 5'-CTC 3'	28 5'-TCg 3'	361 5'-AgT 3'	412 5'-ATA 3'	368 5'-gTT 3'	28 5'-TCg 3'
		678 5'-AgA 3'	142 5'-TCA 3'	630 5'-AAg 3'						414 5'-gAA 3'		678 5'-AgA 3'
				662 5'-CCg 3'								
3'-primer(s) <sup>3</sup>	490 5'-AgT 3'	281 5'-A.T 3'	265 5'-CCC 3'	539 5'-TCT 3'	452 5'-..T 3'	221 5'-ACA 3'	137 5'-TgC 3'	127 5'-CTT 3'	453 5'-TCT 3'	570 5'-CCg 3'	559 5'-CAg 3'	131 5'-ggA 3'
	570 5'-CAg 3'	290 5'-CAA 3'		831 5'-TCC 3'	485 5'-.CA 3'	239 5'-gCT 3'	293 5'-ggA 3'				582 5'-TAg 3'	775 5'-AgT 3'
	583 5'-gTg 3'	316 5'-gAA 3'			559 5'-CTC 3'	247 5'-.TC 3'	295 5'-TCA 3'				605 5'-gCA 3'	843 5'-gTT 3'
		800 5'-ACC 3'				343 5'-.T 3'	299 5'-TCg 3'				614 5'-TgA 3'	852 5'-ACC 3'
		852 5'-ACC 3'					330 5'-TgT 3'					
		895 5'-A 3'										
Well No.	49	50	51	52	53	54	55	56	57	58	59	60

Well No.	61	62	63	64	65	66	67	68	69	70	71	72
Length of spec. PCR product	105	120	135	115	80	155	90	220	115	110	120	120
	165	180			155		230	280	200	200	205	150
	280	280			180				265	255	250	
					235							
Length of int. pos. control <sup>1</sup>	<b>800</b>	<b>800</b>	1070	1070	1070	<b>800</b>	1070	<b>800</b>	1070	1070	<b>800</b>	1070
5'-primer(s) <sup>2</sup>	368 5'-gTT 3'	379 5'-ACA 3'	409 5'-ggC 3'	243 5'-CCT 3'	420 5'-TAg 3'	144 5'-gCC 3'	678 5'-AgA 3'	368 5'-gTT 3'	98 5'-CTC 3'	349 5'-CTT 3'	98 5'-CAC 3'	667 5'-AgA 3'
		476 5'-CAA 3'			420 5'-TAA 3'			1021 5'-gAg 3'		359 5'-CCT 3'	113 5'-CCA 3'	692 5'-ggC 3'
		530 5'-ggT 3'			476 5'-CAA 3'					412 5'-ATA 3'	228 5'-ATg 3'	695 5'-CTC 3'
		542 5'-gAA 3'			504 5'-AAC 3'					499 5'-TCC 3'	678 5'-AgA 3'	699 5'-TAA 3'
					575 5'-gCg 3'							
3'-primer(s) <sup>3</sup>	434 5'-CCC 3'	616 5'-CgT 3'	502 5'-CTT 3'	317 5'-ggA 3'	616 5'-CgT 3'	256 5'-CTg 3'	727 5'-CCA 3'	559 5'-CAg 3'	163 5'-Cgg 3'	570 5'-CCg 3'	317 5'-ggA 3'	777 5'-gCA 3'
	493 5'-CTA 3'						728 5'-CCT 3'	605 5'-gCC 3'	178 5'-gAg 3'		753 5'-gTC 3'	
	605 5'-gCC 3'						866 5'-gAT 3'	610 5'-CTT 3'	180 5'-TCC 3'		842 5'-Tgg 3'	
	614 5'-TgA 3'							614 5'-TgT 3'	256 5'-CTA 3'		843 5'-gTT 3'	
								1047 5'-TT 3'	323 5'-AgC 3'			
									324 5'-TAC 3'			
Well No.	61	62	63	64	65	66	67	68	69	70	71	72



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: November 2022, Rev. No: 00

101.422-24/03 – including *Taq* polymerase  
101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

Well No.	73	74	75	76	77	78	79	80	81	82	83	84
Length of spec.	100	155	145	175	115	140	195	170	100	185	125	105
PCR product	170	195	190	255	145		250	220	215	230	270	210
			285		210					285		290
Length of int.	1070	1070	1070	1070	<b>800</b>	<b>800</b>	1070	1070	1070	1070	<b>800</b>	1070
pos. control <sup>1</sup>												
5'-primer(s) <sup>2</sup>	368 5'-gTT 3'	368 5'-gTT 3'	368 5'-gTT 3'	368 5'-gTT 3'	368 5'-gTT 3'	355 5'-CCA 3'	355 5'-CCg 3'	88 5'-Tgg 3'	368 5'-gTT 3'	98 5'-CTC 3'	98 5'-CTC 3'	368 5'-gTT 3'
				640 5'-Tgg 3'			360 5'-CAC 3'	124 5'-gCC 3'		368 5'-gTT 3'		
				650 5'-CCT 3'			365 5'-gAC 3'	124 5'-gCA 3'				
							416 5'-CCg 3'	142 5'-TCA 3'				
3'-primer(s) <sup>3</sup>	426 5'-TCT 3'	473 5'-CgA 3'	473 5'-CgA 3'	583 5'-gTg 3'	442 5'-gAg 3'	453 5'-TCT 3'	570 5'-CCg 3'	265 5'-CCC 3'	427 5'-gTT 3'	299 5'-TCg 3'	178 5'-gAg 3'	422 5'-AgC 3'
	497 5'-Tgg 3'	493 5'-CTA 3'	518 5'-CCT 3'	587 5'-CCC 3'	473 5'-CgC 3'				536 5'-gCC 3'	343 5'-T 3'	180 5'-TCC 3'	442 5'-gAg 3'
		518 5'-CCA 3'	605 5'-gCA 3'	777 5'-gCA 3'	539 5'-TCC 3'				542 5'-CTg 3'	505 5'-gCT 3'	190 5'-ggT 3'	538 5'-gTg 3'
		525 5'-ACT 3'	610 5'-CTT 3'						553 5'-CTg 3'	517 5'-CgT 3'	324 5'-TAC 3'	616 5'-CCT 3'
			616 5'-CgT 3'							553 5'-CTT 3'	330 5'-TgT 3'	617 5'-CCA 3'
											333 5'-CTg 3'	
Well No.	73	74	75	76	77	78	79	80	81	82	83	84

Well No.	85	86	87	88	89	90	91	92	93	94	95
Length of spec.	145	190	90	75	75	100	80	150	170	105	115
PCR product	210	255	120	170	220	180	270	185	245	190	145
			190	420	270	265			270	220	260
						290				265	355
Length of int.	1070	1070	1070	1070	1070	1070	1070	1070	1070	<b>800</b>	1070
pos. control <sup>1</sup>											
5'-primer(s) <sup>2</sup>	98 5'-CTT 3'	349 5'-CTT 3'	368 5'-gTT 3'	17 5'-gCT 3'	89 5'-gAA 3'	368 5'-gTT 3'	368 5'-gTT 3'	626 5'-CCA 3'	89 5'-gAA 3'	368 5'-gTT 3'	317 5'-gCT 3'
	159 5'-gAA 3'	358 5'-TCg 3'		134 5'-CCA 3'	140 5'-CAC 3'			630 5'-AAT 3'	113 5'-CCA 3'		678 5'-AgA 3'
		359 5'-C.A 3'		141 5'-ATg 3'	282 5'-CAg 3'			640 5'-Tgg 3'	186 5'-Agg 3'		
		416 5'-CCg 3'		232 5'-AgT 3'				667 5'-AgA 3'	186 5'-AgA 3'		
		419 5'-gTC 3'									
3'-primer(s) <sup>3</sup>	265 5'-CCC 3'	570 5'-CCg 3'	418 5'-gTC 3'	265 5'-CCC 3'	317 5'-ggA 3'	421 5'-ggT 3'	397 5'-gAg 3'	777 5'-gCA 3'	317 5'-ggA 3'	430 5'-gCT 3'	391 5'-CCA 3'
			448 5'-CAC 3'			430 5'-gCT 3'	399 5'-AgC 3'			518 5'-CCT 3'	753 5'-gTC 3'
			518 5'-CCA 3'			506 5'-TgA 3'	419 5'-gT 3'			549 5'-AgC 3'	775 5'-AgT 3'
			521 5'-ggA 3'			594 5'-CCT 3'	595 5'-CCA 3'			594 5'-CCT 3'	784 5'-ATg 3'
						616 5'-CCT 3'					895 5'-A 3'
						616 5'-CgC 3'					
Well No.	85	86	87	88	89	90	91	92	93	94	95



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: November 2022, Rev. No: 00

101.422-24/03 – including *Taq* polymerase  
101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **3R9**

#### Lot-specific information

<sup>1</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

<sup>2</sup>The nucleotide position matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>3</sup>The nucleotide position matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: November 2022, Rev. No: 00

101.422-24/03 – including *Taq* polymerase  
 101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

CELL LINE VALIDATION SHEET																				
HLA-A*24 SSP subtyping kit <sup>2</sup>																				
				Prod. No.	Well															
					1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
					201903901	201903902	202245103	201903904	202245105	201903906	202020607	201903908	201903909	201903910	201903911	201903912	201903913	201903914	201903915	201903916
	IHWC cell line <sup>1</sup>	A*	A*																	
1	9001 SA	*24:02			+	-	+	-	+	-	+	-	-	+	-	-	+	-	-	-
2	9280 LK707	*02:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3	9011 E4181324	*01:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4	9275 GU373	*30:01			-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
5	9009 KAS011	*01:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	9353 SM	*02:01	*26:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	9020 QBL	*26:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
8	9025 DEU	*31:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	9026 YAR	*26:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	9107 LKT3	*24:02			+	-	+	-	+	-	+	-	-	+	-	-	+	-	-	-
11	9051 PITOUT	*29:02			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	9052 DBB	*02:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	9004 JESTHOM	*02:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071 OLGA	*31:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15	9075 DKB	*24:02			+	-	+	-	+	-	+	-	-	+	-	-	+	-	-	-
16	9037 SWEIG007	*29:02			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	9282 CTM3953540	*03:01	*80:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18	9257 32367	*33:03	*74:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	9038 BM16	*02:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	9059 SLE005	*02:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	9064 AMALA	*02:17			-	+	-	+	W	-	-	-	-	+	-	-	-	-	-	-
22	9056 KOSE	*02:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
23	9124 IHL	*02:01	*34:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
24	9035 JBUSH	*32:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	9049 IBW9	*33:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
26	9285 WT49	*02:05			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
27	9191 CH1007	*24:10	*29:01		+	+	+	-	+	-	+	-	-	+	-	-	-	-	-	-
28	9320 BEL5GB	*02:01	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29	9050 MOU	*29:02			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	9021 RSH	*30:01	*68:02		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
31	9019 DUCAF	*30:02			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
32	9297 HAG	*02:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	9098 MT14B	*31:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	9104 DHIF	*31:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
35	9302 SSTO	*32:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	9024 KT17	*02:06	*11:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
37	9065 HHKB	*03:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
38	9099 LZL	*02:17			-	+	-	+	W	-	-	-	-	+	-	-	-	-	-	-
39	9315 CML	*01:01	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
40	9134 WHONP199	*02:07	*30:01		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
41	9055 H0301	*03:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
42	9066 TAB089	*02:07			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	9076 T7526	*02:06	*02:07		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
44	9057 TEM	*66:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
45	9239 SHJO	*23:01	*24:02		+	-	+	+	+	+	+	-	-	+	-	-	+	-	-	-
46	9013 SCHU	*03:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	9045 TUBO	*02:16	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
48	9303 TER-ND	*02:01	*11:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-





101.422-24/03 – including *Taq* polymerase  
 101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

CELL LINE VALIDATION SHEET																				
HLA-A*24 SSP subtyping kit <sup>2</sup>																				
				Well																
				17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	
				Prod. No.	201903917	201903918	201903919	201903920	202245121	201903922	201903923	202245124	201903925	201903926	201903927	201903928	201903929	201903930	201903931	201903932
	IHWC cell line <sup>1</sup>	A*	A*																	
1	9001 SA	*24:02		-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	
2	9280 LK707	*02:01		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	
3	9011 E4181324	*01:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
4	9275 GU373	*30:01		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	
5	9009 KAS011	*01:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
6	9353 SM	*02:01	*26:03	-	-	-	-	-	+	+	-	-	-	-	-	-	-	-	-	
7	9020 QBL	*26:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
8	9025 DEU	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
9	9026 YAR	*26:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
10	9107 LKT3	*24:02		-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	
11	9051 PITOUT	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
12	9052 DBB	*02:01		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	
13	9004 JESTHOM	*02:01		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	
14	9071 OLGA	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
15	9075 DKB	*24:02		-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	
16	9037 SWEIG007	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
17	9282 CTM3953540	*03:01	*80:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
18	9257 32367	*33:03	*74:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
19	9038 BM16	*02:01		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	
20	9059 SLE005	*02:01		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	
21	9064 AMALA	*02:17		-	-	-	-	-	+	-	-	+	-	-	-	-	-	-	-	
22	9056 KOSE	*02:01		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	
23	9124 IHL	*02:01	*34:01	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	
24	9035 JBUSH	*32:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
25	9049 IBW9	*33:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
26	9285 WT49	*02:05		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	
27	9191 CH1007	*24:10	*29:01	+	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	
28	9320 BEL5GB	*02:01	*29:02	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	
29	9050 MOU	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
30	9021 RSH	*30:01	*68:02	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	
31	9019 DUCAF	*30:02		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	
32	9297 HAG	*02:01		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	
33	9098 MT14B	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
34	9104 DHIF	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
35	9302 SSTO	*32:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
36	9024 KT17	*02:06	*11:01	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	
37	9065 HHKB	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
38	9099 LZL	*02:17		-	-	-	-	-	+	-	-	+	-	-	-	-	-	-	-	
39	9315 CML	*01:01	*03:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
40	9134 WHONP199	*02:07	*30:01	-	-	-	-	-	+	-	+	-	-	-	-	-	-	-	-	
41	9055 H0301	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
42	9066 TAB089	*02:07		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	
43	9076 T7526	*02:06	*02:07	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	
44	9057 TEM	*66:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
45	9239 SHJO	*23:01	*24:02	-	-	+	-	-	-	-	-	+	-	-	-	-	-	-	-	
46	9013 SCHU	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
47	9045 TUBO	*02:16	*03:01	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	
48	9303 TER-ND	*02:01	*11:01	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	



0197

101.422-24/03 – including *Taq* polymerase  
 101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

CELL LINE VALIDATION SHEET																				
HLA-A*24 SSP subtyping kit <sup>2</sup>																				
				Well																
				33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	
				Prod. No.	201903933	201903934	201903935	201903936	201903937	201903938	201903939	201903940	201903941	201903942	201903943	201903944	201903945	201903946	201903947	201903948
	IHWC cell line <sup>1</sup>	A*	A*																	
1	9001 SA	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
2	9280 LK707	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
3	9011 E4181324	*01:01		-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	
4	9275 GU373	*30:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
5	9009 KAS011	*01:01		-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	
6	9353 SM	*02:01	*26:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
7	9020 QBL	*26:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
8	9025 DEU	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
9	9026 YAR	*26:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
10	9107 LKT3	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
11	9051 PITOUT	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
12	9052 DBB	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
13	9004 JESTHOM	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
14	9071 OLGA	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
15	9075 DKB	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
16	9037 SWEIG007	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
17	9282 CTM3953540	*03:01	*80:01	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	
18	9257 32367	*33:03	*74:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
19	9038 BM16	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
20	9059 SLE005	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
21	9064 AMALA	*02:17		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
22	9056 KOSE	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
23	9124 IHL	*02:01	*34:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
24	9035 JBUSH	*32:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
25	9049 IBW9	*33:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
26	9285 WT49	*02:05		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
27	9191 CH1007	*24:10	*29:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
28	9320 BEL5GB	*02:01	*29:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
29	9050 MOU	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
30	9021 RSH	*30:01	*68:02	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	
31	9019 DUCAF	*30:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
32	9297 HAG	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
33	9098 MT14B	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
34	9104 DHIF	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
35	9302 SSTO	*32:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
36	9024 KT17	*02:06	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
37	9065 HHKB	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
38	9099 LZL	*02:17		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
39	9315 CML	*01:01	*03:01	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	
40	9134 WHONP199	*02:07	*30:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
41	9055 H0301	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
42	9066 TAB089	*02:07		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
43	9076 T7526	*02:06	*02:07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
44	9057 TEM	*66:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
45	9239 SHJO	*23:01	*24:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
46	9013 SCHU	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
47	9045 TUBO	*02:16	*03:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
48	9303 TER-ND	*02:01	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	



0197

101.422-24/03 – including *Taq* polymerase  
 101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

CELL LINE VALIDATION SHEET																				
HLA-A*24 SSP subtyping kit <sup>2</sup>																				
				Well																
				49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	
				Prod. No.	201903949	201903950	201903951	201903952	201903953	201903954	201903955	201903956	201903957	201903958	201903959	201903960	201903961	201903962	201903963	201903964
	IHWC cell line <sup>1</sup>	A*	A*																	
1	9001 SA	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
2	9280 LK707	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
3	9011 E4181324	*01:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
4	9275 GU373	*30:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
5	9009 KAS011	*01:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
6	9353 SM	*02:01	*26:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
7	9020 QBL	*26:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
8	9025 DEU	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
9	9026 YAR	*26:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
10	9107 LKT3	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
11	9051 PITOUT	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
12	9052 DBB	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
13	9004 JESTHOM	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
14	9071 OLGA	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
15	9075 DKB	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
16	9037 SWEIG007	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
17	9282 CTM3953540	*03:01	*80:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
18	9257 32367	*33:03	*74:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
19	9038 BM16	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
20	9059 SLE005	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
21	9064 AMALA	*02:17		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
22	9056 KOSE	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
23	9124 IHL	*02:01	*34:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
24	9035 JBUSH	*32:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
25	9049 IBW9	*33:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
26	9285 WT49	*02:05		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
27	9191 CH1007	*24:10	*29:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
28	9320 BEL5GB	*02:01	*29:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
29	9050 MOU	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
30	9021 RSH	*30:01	*68:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
31	9019 DUCAF	*30:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
32	9297 HAG	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
33	9098 MT14B	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
34	9104 DHIF	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
35	9302 SSTO	*32:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
36	9024 KT17	*02:06	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
37	9065 HHKB	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
38	9099 LZL	*02:17		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
39	9315 CML	*01:01	*03:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
40	9134 WHONP199	*02:07	*30:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
41	9055 H0301	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
42	9066 TAB089	*02:07		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
43	9076 T7526	*02:06	*02:07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
44	9057 TEM	*66:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
45	9239 SHJO	*23:01	*24:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
46	9013 SCHU	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
47	9045 TUBO	*02:16	*03:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
48	9303 TER-ND	*02:01	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	



0197

101.422-24/03 – including *Taq* polymerase  
101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

CELL LINE VALIDATION SHEET																				
HLA-A*24 SSP subtyping kit <sup>2</sup>																				
				Well																
				65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	
				Prod. No.	201903965	201903966	201903967	201903968	201903969	201903970	201903971	201903972	201903973	201903974	201903975	201903976	201903977	201903978	201903979	201903980
IHCW cell line <sup>1</sup>		A*	A*																	
1	9001 SA	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
2	9280 LK707	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
3	9011 E4181324	*01:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
4	9275 GU373	*30:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
5	9009 KAS011	*01:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
6	9353 SM	*02:01	*26:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
7	9020 QBL	*26:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
8	9025 DEU	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
9	9026 YAR	*26:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
10	9107 LKT3	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
11	9051 PITOUT	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
12	9052 DBB	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
13	9004 JESTHOM	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
14	9071 OLGA	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
15	9075 DKB	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
16	9037 SWEIG007	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
17	9282 CTM3953540	*03:01	*80:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
18	9257 32367	*33:03	*74:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
19	9038 BM16	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
20	9059 SLE005	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
21	9064 AMALA	*02:17		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	
22	9056 KOSE	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
23	9124 IHL	*02:01	*34:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
24	9035 JBUSH	*32:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
25	9049 IBW9	*33:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
26	9285 WT49	*02:05		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
27	9191 CH1007	*24:10	*29:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
28	9320 BEL5GB	*02:01	*29:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
29	9050 MOU	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
30	9021 RSH	*30:01	*68:02	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	
31	9019 DUCAF	*30:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
32	9297 HAG	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
33	9098 MT14B	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
34	9104 DHIF	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
35	9302 SSTO	*32:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
36	9024 KT17	*02:06	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
37	9065 HHKB	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
38	9099 LZL	*02:17		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	
39	9315 CML	*01:01	*03:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
40	9134 WHONP199	*02:07	*30:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
41	9055 H0301	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
42	9066 TAB089	*02:07		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
43	9076 T7526	*02:06	*02:07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
44	9057 TEM	*66:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
45	9239 SHJO	*23:01	*24:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
46	9013 SCHU	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
47	9045 TUBO	*02:16	*03:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
48	9303 TER-ND	*02:01	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	



0197

101.422-24/03 – including *Taq* polymerase  
101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

CELL LINE VALIDATION SHEET																			
HLA-A*24 SSP subtyping kit <sup>2</sup>																			
				Well															
				81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	
				Prod. No.	201903981	201903982	201903983	201903984	201903985	201903986	201903987	201903988	201903989	201903990	201903991	201903992	201903993	201903994	201903995
	IHWC cell line <sup>1</sup>	A*	A*																
1	9001 SA	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
2	9280 LK707	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
3	9011 E4181324	*01:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
4	9275 GU373	*30:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
5	9009 KAS011	*01:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
6	9353 SM	*02:01	*26:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
7	9020 QBL	*26:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
8	9025 DEU	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
9	9026 YAR	*26:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
10	9107 LKT3	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
11	9051 PITOUT	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
12	9052 DBB	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
13	9004 JESTHOM	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
14	9071 OLGA	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
15	9075 DKB	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
16	9037 SWEIG007	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
17	9282 CTM3953540	*03:01	*80:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
18	9257 32367	*33:03	*74:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
19	9038 BM16	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
20	9059 SLE005	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
21	9064 AMALA	*02:17		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
22	9056 KOSE	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
23	9124 IHL	*02:01	*34:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
24	9035 JBUSH	*32:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
25	9049 IBW9	*33:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
26	9285 WT49	*02:05		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
27	9191 CH1007	*24:10	*29:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
28	9320 BEL5GB	*02:01	*29:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
29	9050 MOU	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
30	9021 RSH	*30:01	*68:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
31	9019 DUCAF	*30:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
32	9297 HAG	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
33	9098 MT14B	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
34	9104 DHIF	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
35	9302 SSTO	*32:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
36	9024 KT17	*02:06	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
37	9065 HHKB	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
38	9099 LZL	*02:17		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
39	9315 CML	*01:01	*03:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
40	9134 WHONP199	*02:07	*30:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
41	9055 H0301	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
42	9066 TAB089	*02:07		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
43	9076 T7526	*02:06	*02:07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
44	9057 TEM	*66:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
45	9239 SHJO	*23:01	*24:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
46	9013 SCHU	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
47	9045 TUBO	*02:16	*03:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
48	9303 TER-ND	*02:01	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	



0197

101.422-24/03 – including *Taq* polymerase  
 101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **3R9**

**Lot-specific information**

<sup>1</sup>The provided cell line HLA specificities are retrieved from the <http://www.ihwg.org/hla> web site. The specificity of an individual cell line may thus be subject to change.

<sup>2</sup>The specificity of each primer solution in the kit has been tested against 48 well characterized cell line DNAs and where applicable, additional cell line DNAs.

No DNAs carrying the alleles to be amplified by primer solutions 8, 11, 21, 26 to 29, 35, 36, 38, 39, 41 to 43, 45, 47, 50 to 72, 74 to 77, 79 to 86, 88 and 90 to 95 were available. The specificities of the primers in primer solutions 8, 11, 26 to 29, 36, 38, 39, 41, 42, 45, 47, 51, 53, 54, 56 to 59, 63, 64, 68, 70, 71, 76, 77, 79, 80, 82, 84, 85, 88, 90, 91, 93 and 95 were tested by separately adding one, two or three additional 5'-primers, respectively one, two or three additional 3'-primers.

In primer solutions 21, 43, 50, 55, 60, 61, 66, 67, 69, 74, 75, 81, 83 and 94 it was only possible to test the 5'-primers, the 3'-primers were not possible to test.

In primer solutions 35, 52, 62, 65, 72, 86 and 92 it was only possible to test the 3'-primers, the 5'-primers were not possible to test.

In primer solutions 7, 10, 22, 28, 29, 36, 38, 39, 41, 45, 47, 51, 68, 70, 71, 76, 79, 80, 85, 88, 89 and 93 one or more 5'-primers were not possible to test, and in primer solutions 1, 4, 11, 13, 15, 17, 23, 28, 29, 31, 33, 37, 40, 42, 45, 49, 53, 54, 59, 68, 71, 73, 76, 77, 82, 84, 87, 90, 91 and 95 one or more 3'-primers were not possible to test.

Additional primers in primer solutions 4, 15, 22, 25, 30, 33, 40, 49 and 89 were tested by separately adding additional 5'-primers or 3'-primers.



**0197**

For *In Vitro* Diagnostic Use

MA123 v02 SSP PI Template

Date: November 2022, Rev. No: 00

101.422-24/03 – including *Taq* polymerase  
101.422-24u/03u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **3R9**

Lot-specific information

## ADDRESSES:

### Manufacturer:

**CareDx AB**, Franzengatan 5, SE-112 51 Stockholm, Sweden.

Tel: +46-8-508 939 00

**Fax:** +46-8-717 88 18

**E-mail:** [orders-se@caredx.com](mailto:orders-se@caredx.com)

**Web page:** [www.caredx.com](http://www.caredx.com)

**CareDx Lab Solutions Inc.**, 901 S. Bolmar St., Suite R, West Chester, PA 19382

**Tel:** 1-877-653-78171

**Fax:** 610-344-7989

**E-mail:** [orders-us@caredx.com](mailto:orders-us@caredx.com)

**Web page:** [www.caredx.com](http://www.caredx.com)

For information on CareDx distributors worldwide, contact **CareDx AB**.



**0197**

For *In Vitro* Diagnostic Use

MA123 v02 SSP PI Template

Date: November 2022, Rev. No: 00